PART I –- FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Q BIOMED INC.

Condensed Consolidated Balance Sheets


	As of February 28,		As of November 30,
	2023		2022
	(Unaudited)		(Unaudited)
ASSETS
Current assets:
Cash	$	23,173	$	49,973
Accounts receivable		—		11,535
Prepaid expenses and other current assets		10,808		10,808
Total current assets		33,981		72,316
Investment		3,143,201		3,143,201
Intangible assets, net		287,500		300,000
Total Assets	$	3,464,682	$	3,515,517

LIABILITIES AND STOCKHOLDERS‘ DEFICIT
Current liabilities:
Accounts payable	$	2,252,619	$	2,132,063
Accrued expenses		3,221,201		1,545,052
Accrued interest payable		257,297		254,686
Debt		4,083,262		4,109,981
Derivative liabilities		91,158		91,158
Total current liabilities		9,905,733		8,132,940
Total Liabilities		9,905,733		8,132,940

Commitments and Contingencies (Note 8)

Stockholders' Deficit:
Preferred stock, $0.001 par value; 100,000,000 shares authorized as of February 28, 2023 and November 30, 2022		—		—
Convertible Series A, 500,000 shares designated - 227,998 shares issued and outstanding at February 28, 2023 and November 30, 2022, respectively		2,206,516		2,160,916
Convertible Series B, 1,000,000 shares designated - 296,000 shares issued and outstanding at February 28, 2023 and November 30, 2022, respectively		2,933,823		2,874,623
Convertible Series C, 100,000,000 shares designated – 1,000,000 shares issued and outstanding at February 28, 2023 and November 30, 2022, respectively		50,000		50,000
Common stock, $0.001 par value; 250,000,000 shares authorized; 133,027,272 and 84,328,041 shares issued and outstanding as of February 28, 2023 and November 30, 2022, respectively		133,027		84,328
Additional paid-in capital		56,552,997		56,308,513
Accumulated deficit		(68,317,414)		(66,095,802)
Total Stockholders' Deficit		(6,441,051)		(4,617,422)
Total Liabilities and Stockholders' Deficit	$	3,464,682	$	3,515,517

August 31, 2017 November 30, 2016
(Unaudited)
ASSETS
Current assets:
Cash $ 2,499,169 $ 1,468,724
Prepaid expenses 5,000 -
Total current assets 2,504,169 1,468,724
Total Assets $ 2,504,169 $ 1,468,724

LIABILITIES AND STOCKHOLDERS' EQUITY DEFICIT
Current liabilities:
Accounts payable and accrued expenses $ 382,055 $ 497,936
Accrued expenses - related party 17,500 70,502
Accrued interest payable 33,299 48,813
Convertible notes payable (See Note 5) 1,922,474 2,394,849
Note payable 138,856 100,152
Warrant liability - 168,070
Total current liabilities 2,494,184 3,280,322

Long-term liabilities:
Convertible notes payable (See Note 5) - 231,517
Total long term liabilities - 231,517
Total Liabilities 2,494,184 3,511,839

Commitments and Contingencies (Note 6)

Stockholders' Equity Deficit:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of August 31, 2017 and November 30, 2016 - -
Common stock, $0.001 par value; 250,000,000 shares authorized; 11,496,169 and 9,231,560 shares issued and outstanding as of August 31, 2017 and November 30, 2016, respectively 11,496 9,231
Additional paid-in capital 18,667,736 6,249,357
Accumulated deficit (18,669,247 ) (8,301,703 )
Total Stockholders' Equity Deficit 9,985 (2,043,115 )
Total Liabilities and Stockholders' Equity Deficit $ 2,504,169 $ 1,468,724
The accompanying notes are an integral part of these condensed consolidated financial statements

~~Q BioMed Inc.~~

~~Condensed Consolidated Statements of Operations~~

~~(Unaudited)~~

For the three months ended August 31, For the nine months ended August 31,
2017 2016 2017 2016
Operating expenses:
General and administrative expenses $ 3,038,018 $ 1,150,964 $ 6,122,565 $ 3,637,868
Research and development expenses 697,966 443,222 2,296,324 663,500
Total operating expenses 3,735,984 1,594,186 8,418,889 4,301,368

Other income (expenses):
Interest expense (202,160 ) (114,847 ) (635,267 ) (304,596 )
Interest income 15 - 123 -
Loss on conversion of debt - (29,032 ) (365,373 ) (89,210 )
Loss on extinguishment of debt (76,251 ) - (76,251 ) -
Loss on issuance of convertible notes - (28,000 ) - (481,000 )
Change in fair value of embedded conversion option 32,983 50,000 (812,017 ) 362,000
Change in fair value of warrant liability - - (59,870 ) -
Total other expenses (245,413 ) (121,879 ) (1,948,655 ) (512,806 )

Net loss $ (3,981,397 ) $ (1,716,065 ) $ (10,367,544 ) $ (4,814,174 )

Net loss per share - basic and diluted $ (0.37 ) $ (0.19 ) $ (1.03 ) $ (0.55 )

Weighted average shares outstanding, basic and diluted 10,816,282 8,909,414 10,074,766 8,784,373

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

Q ~~BIOMED INC.~~

BioMed Inc.

Condensed Consolidated Statements of ~~Cash Flows~~Operations

(Unaudited)


	For the Three Months Ended
	February 28, 2023		February 28, 2022
Net Sales	$	—	$	75,059
Cost of sales		2,500		73,945
Gross income (loss)		(2,500)		1,114
Operating expenses:
General and administrative expenses		439,818		1,096,300
Research and development expenses		2,691		69,268
Total operating expenses		442,510		1,165,568
Loss from operations		(445,010)		(1,164,454)
Other expenses:
Interest expense		276,602		414,377
Change in fair value of embedded derivatives		—		235,817
Loss on debt extinguishment		—		232,100
Settlement of registration liability		—		241,875
Total other expenses		276,602		1,124,169
Net loss		(721,612)		(2,288,623)
Accumulated dividend on convertible preferred stock		(104,800)		(122,808)
Net loss attributable to common stockholders	$	(826,412)	$	(2,411,431)

Net income (loss) per share - basic and diluted	$	(0.02)	$	(0.08)
Weighted average shares outstanding, basic and diluted		108,730,450		29,594,999

~~(Unaudited)~~

For the nine months ended August 31,
2017 2016
Cash flows from operating activities:
Net loss $ (10,367,544 ) $ (4,814,174 )
Adjustments to reconcile net loss to net cash used in operating activities
Issuance of common stock, warrants and options for services 4,181,693 3,039,277
Issuance of common stock for acquired in-process research and development 487,500 -
Change in fair value of embedded conversion option 812,017 (362,000 )
Change in fair value of warrant liability 59,870 -
Accretion of debt discount 525,864 261,672
Loss on conversion of debt 365,373 89,210
Loss on extinguishment of debt 76,251 -
Loss on issuance of convertible debt - 481,000
Changes in operating assets and liabilities:
Prepaid expenses (5,000 ) (10,000 )
Accounts payable and accrued expenses (115,881 ) 363,593
Accrued expenses - related party (53,002 ) 40,000
Accrued interest payable 109,404 42,925
Net cash used in operating activities (3,923,455 ) (868,497 )

Cash flows from financing activities:
Proceeds received from issuance of convertible notes 2,500,000 815,000
Proceeds received from exercise of warrants 70,000 -
Proceeds received for issuance of common stock and warrants , net of offering costs 2,383,900 60,075
Net cash provided by financing activities 4,953,900 875,075

Net increase in cash 1,030,445 6,578

Cash at beginning of period 1,468,724 131,408
Cash at end of period $ 2,499,169 $ 137,986

Non-cash financing activities:
Issuance of common stock upon conversion of convertible notes payable $ 3,540,838 $ 244,897
Issuance of common stock and warrants in exchange for extinguishment of convertible notes payable $ 442,149 $ -
Issuance of warrants to settle accounts payable to related party $ - $ 30,000
Reclassification of warrant liability to equity $ 227,940 $ -

Cash paid for interest $ - $ -
Cash paid for income taxes $ - $ -

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

Q BIOMED INC.

Condensed Consolidated Statements of Changes in Shareholders’ Deficit

(Unaudited)


	For the Three Months Ended February 28, 2023
																	Total
	Series A Preferred Stock			Series B Preferred Stock			Series C Preferred Stock			Common Stock			Additional Paid		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		in Capital		Deficit		Deficit
Balance as of November 30, 2022	227,998	$	2,160,916	296,000	$	2,874,623	1,000,000	$	50,000	84,328,041	$	84,328	$	56,308,513	$	(66,095,802)	$	(4,617,422)
Issuance of common stock to convert notes payable	—		—	—		—	—		—	48,699,231		48,699		333,251		—		381,950
Accumulated dividend on preferred stock	—		45,600	—		59,200	—		—	—		—		(104,800)		—		—
Share based compensation for services	—		—	—		—	—		—	—		—		16,033		—		16,033
Net loss	—		—	—		—	—		—	—		—		—		(721,612)		(721,612)
Balance as of February 28, 2023 (Unaudited)	227,998	$	2,206,516	296,000	$	2,933,823	1,000,000	$	50,000	133,027,272	$	133,027	$	56,552,997	$	(68,317,414)	$	(6,441,051)


	For the Three Months Ended February 28, 2022
																	Total
	Series A Preferred Stock			Series B Preferred Stock			Series C Preferred Stock			Common Stock			Additional Paid		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		in Capital		Deficit		Deficit
Balance as of November 30, 2021	227,998	$	2,161,195	400,000	$	3,915,512	—	$	—	28,647,788	$	28,648	$	53,335,901	$	(64,126,618)	$	(4,685,362)
Issuance of common stock and warrants for cash	—		—	—		—	—		—	400,000		400		99,630		—		100,030
Cash proceeds from warrants modification	—		—	—		—	—		—	—		—		20,000		—		20,000
Issuance common stock for dividend payment on preferred stock	—		(45,600)	—		(80,000)	—		—	277,877		278		125,322		—		—
Issuance of common stock to convert notes payable	—		—	—		—	—		—	1,577,648		1,578		1,052,369		—		1,053,947
Issuance of common stock to extinguish accrued liabilities	—		—	—		—	—		—	26,627		26		9,773		—		9,799
Accumulated dividend on preferred stock	—		44,586	—		78,222	—		—	—		—		(122,808)		—		—
Share based compensation for services	—		—	—		—	—		—	94,925		95		151,420		—		151,515
Share based compensation for warrants modification	—		—	—		—	—		—	—		—		17,019		—		17,019
Adoption of ASU 2020-06	—		—	—		—	—		—	—		—		(290,967)		82,909		(208,058)
Net loss	—		—	—		—	—		—	—		—		—		(2,288,623)		(2,288,623)
Balance as of February 28, 2022 (Unaudited)	227,998	$	2,160,181	400,000	$	3,913,734	—	$	—	31,024,865	$	31,025	$	54,397,659	$	(66,332,332)	$	(5,829,733)

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

Q BIOMED INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	For the Three Months Ended
	February 28, 2023		February 28, 2022
Cash flows from operating activities:
Net loss	$	(721,612)	$	(2,288,623)
Adjustments to reconcile net loss to net cash used in in operating activities
Share based compensation for services		16,033		151,515
Accretion of debt discount		195,582		351,805
Amortization expense		12,500		12,500
Settlement on registration liability		—		241,875
Loss on debt extinguishment		—		232,100
Changes in operating assets and liabilities:
Accounts receivable		11,535		52,389
Prepaid expenses and other current assets		—		(661)
Accounts payable and accrued expenses		296,705		583,974
Accrued interest payable		50,873		33,434
Net cash used in operating activities		(138,187)		(376,856)

Cash flows from financing activities:
Proceeds received from issuance of convertible notes, net		111,387		—
Proceeds received from issuance of common stock and warrants		—		100,030
Cash advances		—		50,000
Proceeds received for warrants modification		—		20,000
Net cash provided by financing activities		111,387		170,030

Net decrease in cash		(294,036)		(206,826)

Cash at beginning of the year		344,009		344,009
Cash at end of the year	$	49,973	$	137,183

Supplemental disclosures for noncash investing and financing activities:
Issuance of common stock to convert notes payable and accrued interest	$	381,950	$	1,053,947
Accumulated dividend on convertible preferred stock	$	104,800	$	122,808
Issuance of common stock for dividend payment on preferred stock	$	—	$	125,600
Issuance of common stock to extinguish accrued liabilities	$	—	$	9,799
Adoption of ASU 2020-06	$	—	$	208,058

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Note 1 - Organization of the Company and Description of the Business

Q BioMed Inc. (“Q BioMed” or), and its wholly owned subsidiaries Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG (collectively, “the Company”), ~~incorporated in the State of Nevada on November 22, 2013,~~ is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or the spinoff of new public companies.

~~On December 7, 2016, the Company formed its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC” (the “Subsidiary”).~~

The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned ~~subsidiary.~~subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Note 2 - Basis of Presentation

and Going Concern

Basis of Presentation

The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted ~~accounting principles~~ in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission ~~("SEC"~~(“SEC”) regarding interim financial reporting. The Condensed Consolidated Balance Sheet as of August 31, 2017, the Condensed Consolidated Statements of Operations for the three and nine months ended August 31, 2017 and 2016, and the Condensed Consolidated Statements of Cash Flows for the nine months ended August 31, 2017 and 2016, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented. The Condensed Consolidated Balance Sheet at November 30, 2016 has been derived from audited financial statements included in the Company's Form 10-K, most recently filed with the SEC on February 28, 2017. The results for the three and nine months ended August 31, 2017 and 2016 are not necessarily indicative of the results expected for the full fiscal year or any other period.

~~The accompanying interim period unaudited~~These condensed consolidated financial statements are unaudited and ~~related financial information included in this Quarterly Report on Form 10-Q~~ should be read in conjunction with the ~~audited~~unaudited consolidated financial statements ~~and notes thereto~~ included in the Company’s Annual Report on Form ~~10-K.~~

~~The Company currently operates~~10-K for the year ended November 30, 2022 that was filed with SEC on May 26, 2023. Certain disclosures included in ~~one business segment focusing on licensing, acquiring~~the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and ~~providing strategic resources to life sciences and healthcare companies. The Company is~~the rules of the SEC. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not ~~organized by market and is managed and operated as one business. A single management team reports to~~be indicative of the ~~chief~~ operating ~~decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business.~~

results for a full year.

Going Concern

The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

The Company has and is ~~pre-revenue, had approximately $2.5 million~~expected to incur net losses and cash outflows from operations in ~~cash as~~pursuit of ~~August 31, 2017. The~~extracting value from its acquired intellectual property. These matters, amongst others, raise substantial doubt about the Company’s ability ~~of the Company~~ to continue as a going ~~concern depends on~~concern.

Management anticipates that the Company ~~obtaining adequate capital~~will have to ~~fund operating losses until it generates adequate cash flows~~raise additional funds and/or generate revenue from ~~operations~~drug sales within twelve months to ~~fund its operating costs~~continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and ~~obligations.~~administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to ~~obtain adequate capital, it could~~raise sufficient funds, management will be forced to futher scale back the Company’s operations or cease ~~operations.~~

~~The Company depends upon~~ its ability, and will continue to attempt, to secure equity and/or debt financing. The Company might not be successful, and without sufficient financing it would be unlikely for the Company to continue as a going concern. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. operations.

Management has determined that there is substantial doubt about the ~~Company's~~Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued.

The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Risk and Uncertainties

COVID 19

The impact of the worldwide spread of a novel strain of coronavirus (“COVID-19”) has been unprecedented and unpredictable, but based on the Company’s current assessment, the Company does not expect any material impact on its long-term strategic plans,

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

operations and its liquidity due to the worldwide spread of COVID-19. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world and its assessment of the impact of COVID-19 may change.

Note 3 –- Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the ~~audited~~unaudited financial statements for the year ended November 30, ~~2016~~2022 included in the Company’s Form 10-K. ~~Since~~

Modification of Equity Classified Awards

From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards. The classification of stock-based awards, including whether such ~~financial statements, there have been no changes~~instruments should be recorded as liabilities or as equity, is reassessed on the modification date.

Induced Conversion of Convertible Preferred Stock

The Company accounts for gains or losses on extinguishment of equity-classified preferred stock as deemed dividends, to be included in the net loss per common stockholder used to calculate earnings per share. The difference between (1) the fair value of the consideration transferred to the holders of the preferred stock and (2) the carrying amount of the preferred stock (net of issuance costs) is subtracted from (or added to) net loss to arrive at net loss available to common stockholders in the calculation of earnings per share.

Sequencing Policy

The Company adopted a sequencing policy under ASC 815-40-35 (“ASC 815”) whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s ~~significant accounting policies.~~

~~Fair value~~inability to demonstrate it has sufficient authorized shares as a result of certain financial instruments

~~Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as~~ with a potentially indeterminable number of ~~August 31, 2017 and November 30, 2016. The respective carrying value of cash and accounts payable approximated their fair values as they are short term in nature.~~

As of August 31, 2017, the estimated aggregate fair value of all outstanding convertible notes payable is approximately $2.3 million. The fair value estimate is based on the estimated option value of the conversion terms, since the strike price of each note series is in-the-money at August 31, 2017. The estimated fair value represents a Level 3 measurement.

~~Recent accounting pronouncements~~

In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standardshares, shares will be ~~effective for the Company on January 1, 2017. The Company adopted the provisions. Adoption did not have a material impact on the Company's financial position, results of operations, or cash flows.~~

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and paymentsallocated on the basis of the ~~nature~~earliest issuance date of potentially dilutive financial instruments, with the ~~underlying cash flows. In situations in which cash receipts and payments have aspects~~earliest financial instruments receiving the first allocation of ~~more than one class~~shares. Pursuant to ASC 815, issuance of ~~cash flows and cannot be separated by source~~stock-based awards to the Company’s employees, non-employees or ~~use,~~directors recognized under ASC 718 are not subject to the ~~appropriate classification should depend on the activity~~sequencing policy. Any modifications of awards (e.g., options or warrants) that ~~is likely~~remain subject to vesting, or any modifications of awards that continue to be held by active employees, are not subject to the ~~predominant source or use~~sequencing policy. Modifications of ~~cash flows for~~vested awards held by non-employees are subject to the ~~item. This new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.~~

sequencing policy.

Recent Accounting Standards

In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business. The amendments in this Update is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Update may be adopted early. The Company adopted the provisions of ASC 2017-01 effective December 1, 2016. Adoption did not have a material impact on the Company's financial position, results of operations, or cash flows.

~~In July 2017,~~May 2021, the FASB issued ASU ~~2017-11,~~2021-04, Earnings Per Share (Topic 260), ~~Distinguishing Liabilities from Equity~~Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic ~~480)~~718), and Derivatives and ~~Hedging (Topic 815)~~Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). ~~The amendments~~This ASU reduces diversity in ~~Part I~~an issuer’s accounting for modifications or exchanges of ~~this Update change the classification analysis~~freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding ~~equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as~~equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a ~~derivative liability at fair value as a result~~modification of the ~~existence~~terms or conditions or an exchange of a ~~down round feature. For~~ freestanding equity-classified written call option that remains equity classified ~~financial instruments,~~after modification or exchange; (2) how an entity should measure the ~~amendments require entities~~effect of a modification or an exchange of a freestanding equity-classified written call option that ~~present earnings per share (EPS) in accordance with Topic 260 to~~remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of ~~the down round feature when it is triggered. That effect is treated as~~ a ~~dividend and as~~modification or an exchange of a ~~reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options~~freestanding equity-classified written call option that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update areremains equity classified after modification or exchange. This ASU will be effective for ~~fiscal years, and interim periods within those~~all entities for fiscal years beginning after December 15, ~~2018.~~2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, ~~for all entities,~~ including adoption in an interim period. ~~If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management~~The Company is ~~currently assessing~~still evaluating the impact of adoption the ~~adoption~~ASU 2021-04 on its condensed consolidated financial statements.

Table of ~~ASU 2017-11 will have on the Company’s~~Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial ~~Statements.~~Statements

Recently Adopted Accounting Standards

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company elected to early adopt this guidance on December 1, 2021, on a modified retrospective basis. The adoption resulted in approximately $291,000 decrease in additional paid in capital from the derecognition of the bifurcated equity component, $208,000 increase in debt from the derecognition of the discount associated with the bifurcated equity component and $83,000 decrease to the opening balance of accumulated deficit.

Note 4 –- Loss per share

Basic net loss per share was calculated by dividing net loss by the weighted-average shares of common ~~shares~~stock outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average shares of common ~~shares~~stock outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be ~~anti-dilutive.~~anti-dilutive (amounts are rounded to nearest thousand).


Potentially dilutive securities	February 28, 2023	November 30, 2022
Series A convertible preferred stock	2,280,000	2,280,000
Series B convertible preferred stock	8,457,000	8,457,000
Series C convertible preferred stock	1,000,000	1,000,000
Common stock purchase warrants	11,752,000	11,752,000
Stock Options	4,450,000	4,450,000
Convertible Notes	86,360,000	86,360,000
Potentially dilutive securities	114,299,000	114,299,000

Potentially dilutive securities August 31, 2017 August 31, 2016
Warrants (Note 10) 3,033,995 976,500
Convertible debt (Note 5) 567,407 506,757

Note 5 – Intangible Asset Acquisition

On November 23, 2018, the Company entered into an Asset Sale Agreement (“ASA”) with GE Healthcare Limited (“GE”) whereby the Company acquired GE’s radiopharmaceutical drug, Metastron® and all related intellectual property including, but not limited to sales and distribution data, market authorizations and trademarks for Metastron® in various countries in exchange for an upfront payment of $0.5 million, a one-time milestone payment based on future sales, and royalty payments based on future sales. The Company did not acquire any workforce, manufacturing, inventory, sales agreements, or distribution agreements associated with Metastron®. The first commercial sale of Metastron™ by the Company will occur only after the successful transfer or assignment of all intellectual property, material sales and distribution data, technical transfer, and the establishment of new manufacturing sites by the Company and under the appropriate regulatory filings required by the jurisdictions in which Metastron™ is sold.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

The acquired assets are concentrated in a single asset and the set is not considered a business. As such, the transaction is recognized as the acquisition of a finite-lived intangible asset. The one-time milestone payment based on future sales, and royalty payments based on future sales will be recognized when the payments are probable and estimable, which is expected to be when the related sales targets are achieved and the payments payable to GE. The acquired asset is being amortized on a straight-line basis over its estimated 10-year life. Amortization expense for the three months ended February 28, 2023 and 2022 was $12,500, respectively. The estimated remaining amortization expense for each of the five succeeding fiscal year:


Three month ended February 28,
2023		37,500
2024		50,000
2025		50,000
2026		50,000
2027		50,000
Thereafter		50,000
	$	287,500

Note 6 – Investment

For the year ended November 30, 2022, $3.6 million was converted from Licensing fees and Share awards expensed in Research and Development in recognition of shares received in Investment in an Associate – Mannin. We incurred a $500k loss between the value of shares received and the amount expended in Research and Development.

Note 7 - Debt

The table below summarizes outstanding debt as of February 28, 2023 and November 30, 2022 (amounts are rounded to nearest thousand):


	February 28, 2023		November 30, 2022
Convertible Notes Payable:
Principal value of 2021 Debentures	$	2,408,000	$	2,408,000
Fair value of bifurcated contingent put option		1,099,000		1,099,000
Debt discount		(70,000)		(70,000)
2021 Convertible notes payable, net		3,437,000		3,437,000
Principal value of 2022 Debentures		560,000		560,000
Fair value of bifurcated contingent put option		333,000		333,000
Debt discount		(305,000)		(305,000)
2022 Convertible notes payable, net		588,000		588,000
Principal value of 2023 Debentures, net of conversions		(222,000)		—
Debt discount		196,000		—
2023 Convertible notes payable, net		(82,000)		—
Cash advances		85,000		85,000
Total carrying value of convertible notes payable	$	4,084,000	$	4,110,000

2023 Convertible Notes Payable

2023 Debentures

January 2023 Debenture

On January 12, 2023, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “January Debenture”) in the principal amount of $49,000.

August 31, 2017 November 30, 2016
Series A Notes:
Principal value of 10%, convertible at $2.00 at November 30, 2016. $ - $ 12,500
Fair value of bifurcated embedded conversion option of Series A Notes - 12,000
Debt discount - (2,194 )
Carrying value of Series A Notes - 22,306

Series B Notes:
Principal value of 10%, convertible at $2.00 at November 30, 2016. - 55,000
Fair value of bifurcated embedded conversion option of Series B Notes - 55,000
Debt discount - (19,229 )
Carrying value of Series B Notes - 90,771

Series C Notes:
Principal value of 10%, convertible at $1.55 at November 30, 2016. - 576,383
Fair value of bifurcated embedded conversion option of Series C Notes - 838,000
Debt discount - (250,969 )
Carrying value of Series C Notes - 1,163,414

Series D Notes:
Principal value of 10%, convertible at $1.85 at November 30, 2016. - 160,000
Debt discount - (140,961 )
Carrying value of Series D Notes - 19,039

Series E Notes:
Principal value of 10%, convertible at $2.50 at August 31, 2017 and November 30, 2016. 30,000 180,000
Debt discount (4,062 ) (124,164 )
Carrying value of Series E Notes 25,938 55,836

Convertible Debenture:
Principal value of 5%, convertible at $3.60 and $2.98 at August 31, 2017 and November 30, 2016, respectively. 2,000,000 1,500,000
Fair value of bifurcated contingent put option of Secured Convertible Debenture 2,000 72,000
Debt discount (105,464 ) (297,000 )
Carrying value of Secured Convertible Debenture Note 1,896,536 1,275,000
Total short-term carrying value of convertible notes $ 1,922,474 $ 2,394,849
Total long-term carrying value of convertible notes $ - $ 231,517

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

~~Series A Notes~~

The ~~Series A convertible notes payable~~January Debenture includes an original issue discount of $5,250. The Company also incurred an additional $3,750 of issuance cost resulting from the payment of the lender’s legal fees. The January Debenture has a maturity date of January 12, 2024, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The January Debenture carries an interest rate of 12% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 22% per annum from the due date until payment (the ~~“Series A Notes”~~“Default Interest”) ~~are~~. The Company shall pay ten (10) mandatory monthly payments of $5,488 commencing on March 1, 2023. In the event of default the January Debenture shall become immediately due and payable ~~18 months after~~and the Company shall pay to the lender an amount equal to 150% times the sum of (i) the then outstanding principal amount of the January Debenture plus (ii) accrued and unpaid interest on the unpaid principal amount to the date of payment plus (iii) default interest, if any, shall immediately become due and payable.

February 2023 Debenture

On February 13, 2023, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “February Debenture”) in the principal amount of $62,387.

The February Debenture includes an original issue discount of $8,137. The Company also incurred an additional $4,250 of issuance cost resulting from the payment of the lender’s legal fees. The February Debenture has a maturity date of February 14, 2024, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The February Debenture carries an interest rate of 6% per annum, provided that any principal or interest which is not paid when due shall bear interest at ~~10%~~the rate of 22% per ~~annum. At~~annum from the ~~election~~due date until payment (the “Default Interest”). The lender shall have the right from time to time, and at any time during the period beginning on the date which is one hundred eighty (180) days following the date of the ~~holder,~~February Debenture and ending on the later of: (i) the Maturity Date, or (ii) the date of payment of the default amount (the “Conversion Period”), all or any part of the outstanding and unpaid amount into fully paid and non-assessable shares of Common Stock.

2022 Convertible Notes Payable

2022 Debentures

July 2022 Debenture

On July 1, 2022, the Company entered into a Securities Purchase Agreement with an accredited investor (“DL”) pursuant to which the Company issued to DL a Convertible Promissory Note (the “DL Note”) in the aggregate principal amount of $119,888. The DL Note includes an original issue discount of $16,888 (includes $1,250 due diligence fee retained by DL). The Company also incurred an additional $3,000 of issuance cost resulting from the payment of the lender’s legal fees. The DL Note has a maturity date of July 1, 2023, and the Company has agreed to pay interest on the unpaid principal balance of the DL Note at the rate of 10.0% per annum from the date on which the DL Note is issued (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the DL Note, provided it makes a payment including a prepayment to DL as set forth in the DL Note. The outstanding principal ~~and accrued but unpaid interest under~~amount of the ~~Series A Notes~~DL Note may not be converted prior to the period beginning on the date that is ~~convertible~~180 days following the Issue Date. Following the 180th day, DL may convert the DL Note into shares of the Company’s common stock at ~~any time prior to maturity at~~ a conversion price ~~per share~~ equal to ~~the higher of: (i) forty percent (40%) discount to~~80% of the average ~~closing~~of 3 lowest trading price ~~for the ten (10) consecutive trading days~~with a 10-day look back immediately preceding the ~~notice~~date of ~~conversion or (ii) $1.25 per share. At maturity,~~conversion.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

The contingent share-settled redemption feature, contingent acceleration upon merger, acquisition, and event of default within the DL Note are all contingent put options that are required to be bifurcated as a single compound embedded derivative at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of put option on the merger, acquisition, and event of default by estimating the probability of the occurrence of triggering date (the “Probability factor”) and applying the probability to the discounted maximum redemption premium for any ~~remaining outstanding principal and accrued but unpaid interest outstanding under~~given payment with the ~~Series A Notes will automatically convert into~~following key inputs:


	July 1, 2022
Strike price	$	0.05
Terms (years)		1.0
Volatility		138	%
Risk-free rate		2.8	%
Dividend yield		0	%
Probability factor		20	%

The aggregate fair value of the embedded put option on the issuance date was approximately $104,000, which exceeded the net proceeds of $100,000, resulting in an approximate loss of $4,000 upon the on issuance of the convertible note.

For the three months ended February 28, 2023, the Company issued 14,875,997 shares of ~~the Company’s~~ common stock ~~under~~to convert approximately $120,000 of outstanding debt upon the ~~same terms. As~~conversion.

August 2022 Debenture

On August 10, 2022 (the “Effective Date’), the Company entered into a Securities Purchase Agreement with an accredited investor (“the Lender”) pursuant to which the Company issued to the Lender a Convertible Promissory Note (the “August Note”) in the aggregate principal amount of $275,000 for a purchase price of $250,000. The August ~~31, 2017,~~Note has a maturity date of February 6, 2023, and the Company has ~~no Series A Notes outstanding.~~

~~Series B Notes~~

~~The Series B convertible notes payable (the “Series B Notes”) have~~agreed to pay interest on the ~~same terms as~~unpaid principal balance of the ~~Series A Notes. As~~August Note at the rate of ~~August 31, 2017, the Company has no Series B Notes outstanding.~~

~~Series C Notes~~

~~The Series C convertible notes payable (the “Series C Notes”) are due and payable 18 months after issuance and bear interest at 10%~~10.0% per annum. AtUpon the ~~election~~later of the ~~holder, outstanding principal~~date the obligations under this Note are satisfied or the 6-month anniversary and ~~accrued but unpaid~~for 30 days thereafter, the Lender has the exclusive right to elect conversion of any original issue discount or interest amount due under ~~the Series C Notes is convertible~~this August Note, into shares of the Company’s common stock at a conversion price per share equal to ~~the lesser of a 40% discount~~$0.035. The conversion option does not apply to the average closing price for the 10 consecutive trading days immediately preceding the notice of conversion or $1.55, but in no event shall the conversion price be lower than $1.25 per share. If the average VWAP, as defined in the agreement, for the ten trading days immediately preceding the maturity date $5.00 or more, any remaining outstanding principal ~~and accrued but unpaid interest outstanding under the Series C Notes will automatically convert into shares of the Company’s common stock under the same terms.~~

amount. The terms of the Series C Notes also provided that up until maturity date, the Company cannot enter into any additional, or modify any existing, agreements with any existing or future investors that are more favorable to such investor in relation to the Series D Note holders, unless, the Series C Note holders are provided with such rights and benefits (“Most Favored Nations Clause”). As of August 31, 2017, the Company has no Series C Notes outstanding.

~~Series D Notes~~

The Series D convertible notes payable (the “Series D Notes”) are due and payable 18 months after issuance and bear interest at 10% per annum. At the election of the holder, outstanding principal and accrued but unpaid interest under the Series D Notes is convertible into shares of the Company’s common stock at a fixed conversion price per share equal to $1.85. The Series D Notes automatically convert upon maturity at $1.85 per share if the ten trading days VWAP immediately preceding maturity is $5.00 or greater. Additionally, if the Company’s common shares are up-listed to a senior exchange such as the AMEX or NASDAQ, all monies due under the Series D Notes will automatically convert at $1.85 per share.

The terms of the Series D Notes also included the Most Favored Nations Clause. The Most Favored Nations Clause was viewed as providing the Series D Note holder with down-round price protection. As such, the embedded conversion option ~~in the Series D Note was separately measured~~and contingent put upon an event of default are required to be bifurcated as a single compound embedded derivative at fair value ~~upon~~under ASC 815, because it is not considered to be classified in stockholders’ equity. The subsequent changes in fair value are recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value with the following key inputs:


	August 10, 2022
Strike price	$	0.04
Terms (years)		0.5
Volatility		200	%
Risk-free rate		3.1	%
Dividend yield		0	%

The aggregate fair value of the conversion option on the issuance date was approximately $23,000, which was recognized as an additional debt discount.

As additional consideration for making the August Note, the Company agreed to issue 300,000 unregistered common shares within 10 business days to the Lender (the “Commitment shares”). The commitment to issue the shares was valued at the Effective Date fair value of approximately $11,000 and recognized as an additional debt discount. The commitment is a forward contract, recognized at fair value, as a result of applying the Company’s sequencing policy, and recognized at fair value with ~~subsequent~~ changes in fair value recognized in ~~current earnings.~~the Company’s Condensed Consolidated Statements of Operations until settled on August 24, 2022.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

September 2022 Debenture

On September 30, 2016, the Company amended the Most Favored Nations Clause of the Series D Notes to restrict the Company from taking dilutive action without the Series D note holders’ consent, effectively removing the down-round price protection.

At the amendment date, the conversion price of the amended Series D Notes was below the quoted market price of the Company’s common stock. As such, the Company recognized a beneficial conversion feature equal to the intrinsic value of the conversion price on the amendment date, resulting in a discount to the amended Series D Notes of $160,000 with a corresponding credit to additional paid-in capital. The resulting debt discount is presented net of the related convertible note balance in the accompanying Condensed Consolidated Balance Sheets and is amortized to interest expense over the note’s term. As of August 31, 2017, the Company has no Series D Notes outstanding.

~~Series E Notes~~

The Series E convertible notes payable (the “Series E Notes”) are due and payable 18 months after issuance and bear interest at 10% per annum. At the election of the holder, outstanding principal and accrued but unpaid interest under the Series E Notes is convertible into shares of the Company’s common stock at a fixed conversion price per share equal to $2.50. The Series E Notes automatically convert upon maturity at $2.50 per share if the ten trading days VWAP immediately preceding maturity is $5.00 or greater. Additionally, if the Company’s common shares are up-listed to a senior exchange such as the AMEX or NASDAQ, all monies due under the Series E Notes will automatically convert at $2.50 per share.

At the issuance date, the conversion price of the Series E Notes was below the quoted market price of the Company’s common stock. As such, the Company recognized a beneficial conversion feature equal to the intrinsic value of the conversion price on the amendment date, resulting in a discount to the Series E Notes of approximately $141,000 with a corresponding credit to additional paid-in capital. The resulting debt discount is presented net of the related convertible note balance in the accompanying Condensed Consolidated Balance Sheets and is amortized to interest expense over the note’s term.

~~Secured Convertible Debentures~~

~~On November 29, 2016,~~15, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to ~~place Convertible Debentures~~which the Company sold a convertible debenture (the ~~“Debentures”~~“September Debenture”)~~, which was later amended on March 7, 2017, with a one-year term~~ in the ~~aggregate~~ principal amount of ~~up to $4,000,000. On October 3, 2017, the Company amended the Debentures to extend the~~$102,637.

The September Debenture has a maturity date ~~from November 30, 2017 to November 30, 2018 (see Note 11).~~of September 15, 2023, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The ~~initial closing occurred on November 30, 2016~~September Debenture carries an interest rate of 6% per annum, provided that any principal or interest which is not paid when the Company issued a Debenture for $1,500,000 (“Initial Debenture Note”). The second closing of $1 million was on March 10, 2017 (“Second Debenture Note”), when the registration statement to register for resale all of the shares of common stock into which the Debentures may be converted (the “Conversion Shares”) was filed with the SEC. The remaining balance of $1.5 million was received on April 6, 2017 (“Third Debenture Note”), the date the registration statement was declared effective by the SEC. The Debenturesdue shall bear interest at the rate of 5%22% per ~~annum. In addition,~~annum from the due date until payment (the “Default Interest”). The Company ~~must pay to an affiliate of the holder a fee equal to 5% of the amount of~~may prepay the Debenture at ~~each closing.~~

120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance.

November 2022 Debenture

On November 22, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “November Debenture”) in the principal amount of $62,387.

The November Debenture has a maturity date of November 22, 2023, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The November Debenture carries an interest rate of 6% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 22% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance.

2021 Debenture

February 2021 Debenture

On February 12, 2021, the Company issued a debenture for $0.5 million (the “February Debenture”) pursuant to a securities purchase agreement with an accredited investor dated February 12, 2021. The February Debenture may be converted at any time on or prior to maturity at the lower of ~~$4.00~~$1.15 or 93% of the average of the four lowest daily ~~VWAP of the Company’s common stock~~VWAPs during the ~~ten~~10 consecutive trading days immediately preceding the conversion date, provided that as long as ~~the Company is~~we are not in default under the 2020 Debenture, the conversion price may never be less than ~~$2.00.~~$1.00. The debenture has a maturity date of February 12, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The debenture bears interest at the rate of 5.5% per annum, and on issuance, the Company paid to the holder a commitment fee equal to 2% of the amount of the debenture.

The aggregate fair value of the contingent put options on the issuance date was approximately $28,000, which was recognized as an additional debt discount.

On January 21, 2022, the Company issued 1,055,000 shares of common stock to convert $0.5 million of outstanding debt and interest and extinguished $95,000 of embedded derivative liability upon the conversion. The conversion price was reduced to $0.50. The Company recognized a loss on debt extinguishment of approximately $232,000 as a result of the reduction of conversion price for the three months ended February 28, 2022.

July 2021 Debenture

On July 26, 2021, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “July Debenture”) in the principal amount of $806,250 and a warrant to purchase up to 645,000 shares of common stock (the “Warrant”) for a total purchase price of $750,000. The Company also paid $18,750 for the lender's legal fee.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

The July Debenture has a maturity date of April 26, 2022, provided that in case of an event of default, the debenture may become at the holder's election immediately due and payable. The July Debenture carries an interest rate of 10% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 15% per annum from the due date until payment (the “Default Interest”). The Company may ~~not convert any portion~~prepay the Debenture at 120% of the ~~Debenture if such conversion would result in~~outstanding aggregate principal amount within the ~~holder beneficially owning more than 4.99%~~first 60 days of ~~the Company’s then issued common stock, provided that such limitation may be waived by the holder.~~

~~Any time after the six-month anniversary~~issuance and at 130% of the issuance of the Debenture, if the daily VWAP of the Company’s common stock is less than $2.00 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of ~~(i)~~ the outstanding principal amount, ~~outstanding as of~~ the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount being paid (up to a maximum of $300,000 in redemption premium) and (iii) accrued and unpaid interest ason the unpaid principal amount and any Default Interest from 61 to 180 days after issuance.

The holder may convert the July Debenture in its sole discretion at any time on or prior to maturity at the lower of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93%$1.00 or 85% of the average of the four (4) lowest ~~daily~~VWAPs during the 20 Trading Days prior to the date of such calculation. The “Variable Conversion Price” shall equal, subject to an initial floor price of $0.35 (the “Floor Price”), the lower of $1.00 and 85% of the average of the four (4) lowest VWAPs during the 20 Trading Days prior to the date of such calculation. The initial Floor Price shall be readjusted to $0.10 if following the Issue Date, VWAP of the ~~Company’s common stock during the~~Company shall be less than $0.35 for a total of ten ~~consecutive Trading Days immediately preceding the due~~days.

The Warrant has an exercise price of $1.25 and may be exercised in cash or via cashless exercise, exercisable for five (5) years from issuance. The grant date ~~in respect of such monthly payment begin deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder.~~

The Company also entered into a Security Agreement to secure payment and performance of its obligations under the Debenture and related agreements pursuant to which the Company granted the investor a security interest in all of its assets. The security interest granted pursuant to the Security Agreement terminated on the effectiveness of the Registration Statement on April 6, 2017.

Upon issuance of the Second and Third Debenture Notes, the Company recognized a debt discount of $731,000, resulting from the recognition of a beneficial conversion feature of $645,000 and a bifurcated embedded derivative of $86,000. The beneficial conversion feature was recognized as the intrinsicrelative fair value of the ~~conversion option~~Warrant was estimated to be $253,000 as determined based on ~~issuance~~the relative fair value allocation of the ~~Debentures.~~proceeds received. The ~~monthly payment~~Warrant were valued using the Black-Scholes option pricing model using the following inputs:

The contingent share-settled redemption feature and contingent prepayment provision within the ~~Debentures is a~~July Debenture are all contingent put ~~option~~options that isare required to be ~~separately measured~~bifurcated as a single compound embedded derivative at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations during the nine months ended August 31, 2017. The Company estimated the fair value of the monthly payment provision, as of August 31, 2017 and November 30, 2016, using probability analysis of the occurrence of a Triggering Date applied to the discounted maximum redemption premium for any given payment. The probability analysis utilized the following inputs:

~~Volatility~~			~~101.58% - 146.26~~	%
~~Risk-free rate~~			~~0.53% - 1.08~~	%

~~The maximum redemption was discounted at 20%, the calculated effective rate of the Debenture before measurement of the contingent put option.~~Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value with the following key inputs:


	July 1, 2022
Strike price	$	0.05
Terms (years)		1.0
Volatility		138	%
Risk-free rate		2.8	%
Dividend yield		0	%
Probability factor		20	%

The aggregate fair value of the contingent put options on the issuance date was approximately $209,000, which was recognized as an additional debt discount.

On December 15, 2021, the Company and the holder entered into a Mutual Release Agreement pursuant to which the holder agreed to add the $241,875 to the outstanding principal balance of July Debenture, for no consideration received by the Company, in order to resolve a breach of certain registration provisions of the securities purchase agreement.

The July Debenture is past maturity and is currently in default. However, the Company has not received any default notice from the holder.

During the year ended November 30, 2022, the Company issued an aggregate 3,633,862 shares of common stock to convert approximately $413,000 of outstanding debt and extinguished approximately $159,000 embedded derivative liability upon the conversion. The Company recognized a loss on debt extinguishment of approximately $152,000 as a result of the reduction of conversion price for the year ended November 30, 2022.

September 2021 Debenture

On September 29, 2021, the Company entered into a securities purchase agreement with an accredited investor (“Lender”), pursuant to which the Company sold a convertible debenture (the “September Debenture”) in the principal amount of $2,200,000 with twelve-months term. The September Debenture includes an original issue discount of $185,000 and $15,000 for the payment of the Lender’s legal fees and carries an interest rate of 6% per annum. The Company also incurred other issuance costs of $247,350. On October 26, 2021, the September Debenture maturity date was extended for an additional 3 months to December 20, 2022.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

~~Embedded~~

The Company may prepay the September Debenture at 105% of the outstanding aggregate principal amount plus accrued interest within the first 60 days of issuance, at 112% of the outstanding aggregate principal amount plus accrued interest from 61-120 days after issuance and at 124% of the outstanding aggregate principal amount plus accrued interest from 121-180 days after issuance. The Debenture may not be prepaid after 180 days.

The Lender has the right to convert all or any amount of the outstanding aggregate principal amount at any time at a fixed conversion price of $1.00 per share. The conversion price after six months shall be fixed at $0.50 per share.

However, in the event the Company’s Common Stock trades below $0.50 per share for more than ten (10) consecutive trading days, the Lender is entitled to convert all or any amount of the outstanding aggregate principal amount into shares of the Company’s Common Stock at a Conversion ~~Options~~

~~The embedded~~Price for each share of Common Stock equal to 85% of the average of the 4 lowest VWAP’s in the prior 20 trading days. As a result of entering into the “September Debenture”, for which such instruments contained a variable conversion feature with no floor, the Company has adopted sequencing policy (see Note 3).

The contingent share-settled redemption feature and contingent prepayment provision within the September Debenture are all contingent put options that are required to be bifurcated as a single compound embedded derivative at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is ~~separately measured~~a Level 3 measurement. The Company estimated the fair value with the following key inputs:


	September 29, 2021
Strike price	$	0.50
Terms (years)		1.0
Volatility		66	%
Risk-free rate		0.1	%
Dividend yield		—	%

The aggregate fair value of the contingent put options on the issuance date was approximately $278,000, which was recognized as an additional debt discount.

On April 8, 2022, the Company issued 245,000 shares of common stock as commitment shares pursuant to the securities purchase agreement. The commitment to issue the shares was valued at the Effective Date fair value of approximately $177,000 and recognized as an additional debt discount. The commitment is a forward contract, recognized at fair value, as a result of applying the Company’s sequencing policy, and recognized at fair value with changes in fair value recognized in ~~current operations. Management used a binomial valuation model, with fourteen steps~~the Company’s Condensed Consolidated Statements of Operations until settled on April 8, 2022.

For the three months ended February 28, 2023, the Company issued 33,823,234 shares of common stock to convert approximately $214,000 of outstanding debt and extinguished $146,000 of embedded derivative liability upon the conversion.

For the year ended November 30, 2022, the Company issued 21,025,054 shares of common stock to convert approximately $305,000 of outstanding debt and extinguished $146,000 of embedded derivative liability upon the conversion.

The fair value of the ~~binomial tree,~~contingent put option in all outstanding debentures with the feature are revalued as of February 28, 2023 and November 30, 2022 based on the following weighted average key inputs:


	February 28, 2023			November 30, 2022
Strike price	$	0.55		$	0.55
Terms (years)		0.3			0.3
Volatility		200	%		200	%
Risk-free rate		2.9	%		2.9	%
Dividend yield		0	%		0	%

Table of Contents

Q BIOMED INC.

Notes to ~~estimate~~Condensed Consolidated Financial Statements

The following table presents changes in Level 3 liabilities measured at fair value for the period ended February 28, 2023 and for the year ended November 30, 2022. Both observable and unobservable inputs were used to determine the fair value of ~~the embedded conversion option at issuance of the Series A, B, C and D Notes with the following key inputs:~~

Embedded derivatives at inception and upon conversion
For the nine months ended August 31,
2017 2016
Stock price $ 4.93 - $7.05 $ 2.60 - $3.26
Terms (years) 0.11 - 0.85 1.5
Volatility 144.26% - 157.35 % 116.77 %
Risk-free rate 0.53% - 0.76 % 0.51% - 0.76 %
Dividend yield 0.00 % 0.00 %

Embedded derivatives at period end
August 31, 2017 November 30, 2016
Stock price - $ 3.43
Term (years) - 0.25 - 1.05
Volatility - 156.74% - 163.49 %
Risk-free rate - 0.48% - 0.80 %
Dividend yield - 0.00 %

~~During the three months ended August 31, 2017 and 2016,~~positions that the Company ~~recognized interest expense of approximately $171,000~~has classified within the Level 3 category. Unrealized gains and ~~$97,000, respectively, resulting from amortization of~~losses associated with liabilities within the debt discount for the outstanding convertible notes. During the nine months ended August 31, 2017 and 2016, the Company recognized interest expense of approximately $526,000 and $262,000, respectively, resulting from amortization of the debt discount for the outstanding convertible notes.

As of August 31, 2017, the embedded conversion options have an aggregate fair value of $2,000 and are presented on a combined basis with the related loan host in the Company’s Condensed Consolidated Balance Sheets. The table below presentsLevel 3 category include changes in fair value ~~for the embedded conversion options, which is a Level 3 fair value measurement:~~that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (amounts are rounded to nearest thousand:


Balance November 30, 2021	$	867,000
Issuance of convertible notes		271,000
Debt extinguishment		(425,000)
Change in fair value		721,000
Balance November 30, 2022	$	1,434,000
Issuance of convertible notes		—
Change in fair value		—
Balance February 28, 2023	$	1,434,000

Rollforward of Level 3 Fair Value Measurement for the Nine Months Ended August 31, 2017

Balance at November 30, 2016 Issuance Net unrealized gain/(loss) Conversion Balance at August 31, 2017
$ 977,000 86,000 812,017 (1,873,017 ) $ 2,000

~~Conversions of debt~~

Debt Conversion

The following ~~conversions of the convertible notes occurred~~table summarizes debt conversion during the ~~nine months~~period ended ~~August 31, 2017:~~

Principal Shares
Series A conversions 12,500 5,936
Series B conversions 55,000 27,995
Series C conversions 576,383 407,484
Series D conversions 160,000 91,782
Series E conversions 150,000 63,255
Secured Debenture conversions 2,000,000 461,203
Total $ 2,953,883 1,057,655

AsFebruary 28, 2023 and the ~~embedded conversion option in each note series had been separately measured at fair value,~~year ended November 30, 2022 (amounts are rounded to nearest thousand):

Debt Amendment

On October 26, 2021, the ~~conversion~~Company entered into an extension agreement with the holder of ~~each note~~September 2021 Debenture (the "Holder") to extend the maturity date from September 30, 2022, to December 29, 2022. The amendment was recognized as a troubled debt restructuring.

On July 22, 2021, the Company entered into an ~~extinguishment of debt. The Company recognized a loss on conversion of debt of approximately $365,000 as the difference between the fair value of common stock issued~~amendment agreement to the ~~holders of approximately $2.7 million and~~securities purchase agreement with the ~~aggregate net carrying value~~Holder, pursuant to which, the floor price of the ~~convertible notes, including~~2020 Debenture was reduced to $0.50 per share. Additionally, the ~~bifurcated conversion options, of approximately $2.3 million.~~

~~Extinguishment of debt~~

~~On August 1, 2017, the holder~~maturity date of the ~~Debentures retired an aggregate of $250,000 each in principal of the Second and Third~~2020 Debenture ~~Notes along with its accrued interest, for a total amount of approximately $0.5 million,~~was extended to reinvest and purchase an aggregate of 162,000 Units in the August Private Placement (see Note 9). As the embedded conversion option in the Debentures had been separately measured at fair value, the cancellation of debtDecember 31, 2021. The amendment was recognized as ana debt extinguishment, of debt. The Company recognized a loss on extinguishment of debt of approximately $76,000 as the difference between the fair value of Units issued to the holders of approximately $0.5 million and the aggregate net carrying value of the convertible notes, including the bifurcated conversion options, of approximately $442,000.

~~Events of default~~

The Company will be in default of the Series E Notes, and all amounts outstanding will become immediately due and payable upon: (i) maturity, (ii) any bankruptcy, insolvency, reorganization, cessation of operation, or liquidation events, (iii) if any money judgement, writ or similar process filed against the Company for more than $150,000 remains unvacated, unbonded or unstayed for a period of twenty (20) days, (iv) the Company fails to maintain the listing of the common stock on at least one of the OTC markets or the equivalent replacement exchange, (v) the Company’s failure to maintain any material intellectual property rights, personal, real property or other assets that are necessary to conduct its business, (vi) the restatement of any financial statements filed with the U.S. Securities and Exchange Commission (“SEC”) for any period from two years prior to the notes issuance date and until the notes are no longer outstanding, if the restatement would have constituted a material adverse effect of the rights of the holders of the notes, (vii) the Company effectuates a reverse stock split of its common stock without twenty (20) days prior written notice to the notes’ holders, (viii) in the event that the Company replaces its transfer agent but fails to provide, prior to the effective date, a fully executed irrevocable transfer agent instructions signed by the successor transfer agent and the Company, (ix) in the event that the Company depletes the share reserve and fails to increase the number of shares within three (3) business days, (x) if the Company fails to remain current in its filings with the SEC for more than 30 days after the filing deadline, (xi) after 12 months following the date the Company no longer deems itself a shell company as reflected in a ’34 Act filing, the Lenders are unable to convert the notes into free trading shares, and (xii) upon fundamental change of management.

~~The Company is currently not in default for any convertible notes issued.~~

~~Note 6 – Note Payable~~

~~As of August 31, 2017 and November 30, 2017, the Company had an outstanding promissory note of $150,000 (“OID Note”). The OID Note does not pay interest and matures on November 3, 2017.~~

At the issuance date, the $150,000 OID Note was issued together with 15,000 restricted shares of the Company’s common stock for cash proceeds of $150,000. As such, the Company recognized a beneficial conversion feature, resulting in a ~~discount to the OID Note~~gain on debt extinguishment of approximately ~~$52,000 with a corresponding credit to additional paid-in capital. The resulting debt discount is presented net of the related convertible note balance~~$15,000.

Interest expense

Interest expense, included in the accompanying Condensed Consolidated ~~Balance Sheets and~~Statements of Operations, is ~~amortized~~comprised of the following for each period presented (amounts are rounded to ~~interest expense over the note’s term.~~nearest thousand):


	For the Three Months Ended
	February 28, 2023		February 28, 2022
Interest expense based on the coupon interest rate of the outstanding debt	$	51,000	$	61,000
Accretion of debt discount		217,000		352,000
Other		9,000		1,000
Total interest expense	$	277,000	$	414,000

Cash Advances

Cash advances include cash provided by vendors that is subject to repayment on demand.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Note ~~7 –~~8 - Commitments and Contingencies

Equity Financing

On May 5, 2021, the Company entered into an agreement with Aedesius Holdings Ltd. ("Aedesius") pursuant to which the Company has agreed with Aedesius that the Company would sell it up to 16,000,000 units (the "Units") for a total aggregate of up to $20,000,000.

Aedesius failed to perform on its obligation and to date has not invested any monies in the Company. As a result, the Company has terminated any and all rights with respect to future fundings and will pursue whatever rights and remedies the Company has at its disposal for breach of contract and damages.

Legal

Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

As previously reported, on July 12, 2022, the Company was notified that WSI PBG, LLC (“WSI”) filed a complaint against the Company seeking to recover $196,216 in unpaid consulting fees, plus costs and expenses of litigation. The Company elected not to litigate this suit so as not to increase its liability exposure. Not unexpectedly, on August 24, 2022, WSI obtained a judgment against the Company in the amount of $203,784. The Company is exploring its options in addressing this judgment, including terms of settlement that would result in a satisfaction of this Judgment over a limited period of time.

On July 19, 2022, the Company received notice that the Activus Group (“Activus”) filed a complaint for fees it alleges are due in the amount of $129,600 plus fees and expenses for consulting services provided by Activus as a result of an agreement between the parties. The Company has not filed an answer and is currently determining their next steps in settlement.

On August 15, 2022, the Company received notice that another of its unpaid contractors, Diligent Health Solutions, LLC. (“DHS”), had filed suit against the Company seeking $106,000 in unpaid consulting fees. Here, too, the Company elected not to litigate this suit so as not to increase its liability exposure. As a result of the foregoing, DHS obtained a default judgment against the Company in the amount of $111,000. The company is exploring its options in addressing this judgment, including terms of settlement that would result in a satisfy of this Judgment over a limited period of time.

Advisory Agreements

The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received.

On March 11, 2022, the Company entered into an engagement letter agreement (“Agreement”) with EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”) to effectuate the Corporation’s Firm Commitment Public Offering and Uplisting and to engage EF Hutton to act as the placement agent for a bridge or other private offering consisting of approximately $2 million. The Company shall be responsible for EF Hutton’s external counsel’s legal costs irrespective of whether the Offering is consummated or not, subject to a maximum of $50,000 in the event that there is not a Closing. The Company incurred $15,000 of expense during year ended November 30, 2022, and no payment was made as of February 28, 2023.

Lease Agreement

In December 2016, ~~the Subsidiary~~one of our subsidiaries entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ~~ends~~ended in December 2019, and ~~can be~~the Company has renewed its office lease agreement for another

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

three ~~years.~~

years with the same terms. This agreement does not identify a specific asset and does not convey the use of substantially all of the shared office capacity. As such, this agreement does not contain a lease under ASC 842. The Company recognizes monthly license payments as incurred over the term of the arrangement.

Rent ~~expenses was~~expense is classified within general and administrative expenses ~~and was approximately $7,500 and $18,000 for the three and nine months ended August 31, 2017.~~

on a straight-line.

License ~~Agreement~~

Agreements

Mannin

On October 29, 2015, the Company entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License.

On March 26, 2019, the Company entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021, in exchange for the Company issuing 100,000 shares to Mannin Research Inc. on April 9, 2019.

On September 1, 2020, the Company further amended the license agreement allowing Mannin to grant an exclusive license to Mannin GmbH (its wholly owned German subsidiary) in order fully take advantage of the German government grant to Mannin. The agreement also confirms our ongoing investment into the Tie2 platform to create, and therefore maintain economic value for us and our shareholders. The Company has agreed to contribute funds in Mannin GmbH. We shall pay Mannin $1.5 million in cash payable in three instalments, thereof $0.7 million of which has been paid, $0.4 million of which was due on December 31, 2020, and $0.4 million to be paid by June 30, 2021. In addition, we paid Mannin $0.75 million in shares of our common stock valued as of June 15, 2020, in full satisfaction of R&D payables, contracted by Mannin in development of the Tie2 platform. We continue to have the right to 100% of the revenues derived from the Mannin Tie2 technology platform, until such time that Mannin and its subsidiaries have independently raised at least $2.0 million in funds, at which time the parties have agreed to a profit share structure reducing our future capital commitments to Mannin R&D.

During the ~~three~~period ended February 28, 2023 and ~~nine months~~year ended ~~August 31, 2017,~~November 30, 2022, the Company incurred approximately ~~$525,000~~$0.0 and ~~$1.4~~$0.1 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License. ~~Through August 31, 2017,~~

For year ended November 30, 2022, $3.6 million was converted from Licensing fees and Share awards expensed in Research and Development in recognition of shares received in Investment in an Associate - Mannin. We incurred a $500k loss between the ~~Company had funded an aggregate~~value of ~~$2.15 million to Mannin under~~shares received and the ~~Exclusive License.~~

~~Bio-Nucleonics~~

amount expended in Research and Development.

Washington University

On ~~September 6, 2016,~~March 9, 2019, the Company entered into an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the ~~Patent and Technology License and Purchase Option Agreement (the “BNI Exclusive License”) with Bio-Nucleonics Inc. (“BNI”) whereby~~severity of glaucoma using the expression levels of Growth Differentiation Factor 15. The agreement calls for the Company ~~was granted a worldwide, exclusive, perpetual, license on, and option~~ to ~~acquire certain BNI intellectual property (“BNI IP”) within the three-year term of the BNI Exclusive License.~~

During the three and nine months ended August 31, 2017, the Company incurred approximately $144,000 and $352,500, respectively, in research and development expenses pursuant to the BNI Exclusive License. As of August 31, 2017, the Company had paid approximately $351,700 to BNI out of the $850,000 cash funding requirement. The Company is not obligated to provide further funding to BNI until BNI satisfies all of its pre-existing obligations totaling $163,500. To this end, the Company had providedpay an ~~aggregate~~initial fee of approximately ~~$59,000 through August 31, 2017~~$88,000, pay annual maintenance fees ranging from $15,000 to ~~BNI to help settle its obligations, which the Company recognized as research and development expenses in the accompanying Statements of Operations. As of August 31, 2017, this condition was met.~~

~~Asdera~~

On April 21, 2017, the Company entered into a License Agreement on Patent & Know-How Technology (“Asdera License”) with Asdera LLC (“Asdera”) whereby the Company was granted a worldwide, exclusive, license on certain Asdera intellectual property (“Asdera IP”). The initial cost to acquire the Asdera License is $50,000 and the issuance of 125,000 shares of the Company’s common stock, with a fair value of $487,500, of which the Company had fully paid and issued as of August 31, 2017, and recorded in research and development expenses in the accompanying Condensed Consolidated Statements of Operations. In addition to royalties based upon net sales of the product candidate, if any, the Company is required to make certain additional payments upon the following milestones:

-	~~the filing of an investigational new drug application (the “IND”) with the US Food and Drug Administration (“FDA”);~~

-	~~successful interim results of Phase II/III clinical trial of the product candidate;~~

-	~~FDA acceptance of a new drug application;~~

-	~~FDA approval of the product candidate; and~~

-	~~achieving certain worldwide net sales.~~

Subject to the terms of the Agreement, the Company will be in control of the development and commercialization of the product candidate and are responsible for the costs of such development and commercialization. The Company has undertaken a good-faith commitment to (i) initiate a Phase II/III clinical trial at the earlier of the two-year anniversary of the agreement or one year from the FDA’s approval of the IND and (ii) to make the first commercial sale by the fifth-anniversary of the agreement. Failure to show a good-faith effort to meet those goals would mean that the Asdera IP would revert to Asdera. Upon such reversion, Asdera would be obligated to pay the Company royalties on any sales of products derived from the Asdera IP until such time that Asdera has paid the Company twice the sum that the Company had provided Asdera prior to the reversion.

~~OMRF~~

~~OMRF License Agreement~~

On June 15, 2017, the Company entered into a Technology License Agreement (“OMRF License Agreement”) with the Rajiv Gandhi Centre for Biotechnology, an autonomous research institute under the Government of India (“RGCB”), and the Oklahoma Medical Research Foundation (“OMRF” and together with RGCB, the “Licensors”), whereby the Licensors granted the Company a worldwide, exclusive, license on intellectual property related to Uttroside B (the “Uttroside B IP”). Uttroside B is a chemical compound derived from the plant ~~Solanum nigrum Linn, also known as Black Nightshade or Makoi. The Company seeks to use the Uttroside B IP to create a~~ ~~chemotherapeutic agent against liver cancer.~~

The initial cost to acquire the OMRF License Agreement is $10,000, which will be payable upon reaching certain agreed conditions. The Company is expecting to pay this initial cost in the next quarter. In addition to royalties based upon net sales of the product candidate, if any, the Company is required to$75,000, make additional payments upon the following milestones:



~~the completion~~●

The first commercial sale of ~~certain preclinical studies (the “Pre-Clinical Trials”);~~a companion diagnostic product;



~~the filing~~●

Initiation of ~~an investigational new drug application (the “IND”) with the US Food and Drug Administration (“FDA”)~~a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory approval or the ~~filing of the equivalent of an IND with the~~ foreign ~~equivalent of the FDA;~~equivalent;

	~~successful completion of each of Phase I, Phase II and Phase III clinical trials;~~

●	~~FDA approval of the product candidate;~~

	PMA or 510(k) regulatory approval by the FDA or the foreign ~~equivalent of the FDA of the product candidate;~~

	~~achieving certain worldwide net sales;~~equivalent; and

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements



●

The first commercial sale of a ~~change of control of QBIO.~~diagnostic product.

~~Subject~~

In addition to the ~~terms~~above payments, royalty payments based upon sales of ~~the Agreement, the Company will be in control of the development and commercialization of the~~a companion diagnostic product ~~candidate and~~or diagnostic product are responsible for the costs of such development and commercialization. The Company has undertaken a good-faith commitment to (i) fund the Pre-Clinical Trials and (ii) to initiate a Phase II clinical trial within six years of the date of the Agreement. Failure to show a good-faith effort to meet those goals would mean that the RGCB License Agreement would revert to the Licensors.

~~Milestones~~

~~No milestones have been reached to date on these license agreements.~~

required.

Note 89 - Related Party Transactions

The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses ~~associated with related parties~~resulting from such agreements were ~~incurred as follow, and were~~ included within general and administrative expenses in the accompanying Condensed Consolidated Statements of ~~Operations.~~Operations as follows (amounts are rounded to nearest thousand), but have not been paid to date:

For the three months ended August 31, For the nine months ended August 31,
2017 2016 2017 2016
Related parties $ 102,500 $ 104,632 $ 322,500 $ 207,875

On February 1, 2021, the Company issued 35,000 shares to Mr. Rosenstadt, the Company's Chief Legal Officer and director, for his services performed in connection with December 2020 financing. The fair value was approximately $35,000, which was recorded as part of debt issuance cost to the 2020 Debenture (see note 5).

On April 16, 2021, the Company entered into two unsecured promissory note agreements (the "Notes") with certain management personnel for an aggregate principal amount of $30,000. The Notes bear interest at 5% per annum and are payable by August 31, 2021. During the quarter ended August 31, 2021, the Company made full repayment of $30,000 to the management personnel, including all outstanding interest.

On May 29, 2022 the company issued 250,000 shares at a nominal value of 10c per share to Mr. Rosenstadt, the company's Chief Legal Officer and director, in lieu of cash for his monthly services.

On May 29, 2022, the company issued 200,000 shares at a nominal value of 10c per share to Mr Corin, the company's Chief Executive Officer, as partial payment of his monthly salary in lieu of cash.

Note 910 - Stockholders’ ~~Equity~~ Deficit

As of ~~August 31, 2017,~~February 28, 2023 and November 30, 2022, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock.

~~Private Placement~~

~~On August 1, 2017, the Company closed its private placement (“August Private Placement”), selling an aggregate of 953,249 units (“Units”) at a~~

Preferred Shares

The original issue price ~~of $3.20 per Unit, for an aggregate cash proceeds of approximately $2.4 million, net of offering costs,~~ and the ~~retirement~~liquidation value per share, as of ~~$0.5 million in principal and accrued interest~~February 28, 2023, of each class of preferred stock is as follows:


	Original Issue Price		Liquidation Value
	Per Share		Per Share
Series A Preferred Share	$	10.00	$	10.20
Series B Preferred Share	$	10.00	$	10.25
Series C Preferred Share	$	0.05	$	0.05

During the ~~Debentures.~~ ~~A Unit consists of one common stock and one warrant exercisable for five years from the date of issuance into a share of the Company’s common stock at an exercise price of $4.50.~~

~~In connection with the August Private Placement,~~year ended November 30, 2022, the Company issued 1,000,000 of Series C preferred stock in the amount of $50,000 for settlement of an ~~aggregate~~amount due to officers and directors.

The Company had accumulated dividends payable on the Preferred Shares of ~~39,246 warrants~~approximately $105,000 as of February 28, 2023.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Common Shares

Issuance of common shares for services

The Company recognized approximately $16,000 related to the ~~placement agent as consideration. These warrants have the same terms with the warrants issued in the August Private Placement.~~

~~In January 2017, the Company issued 20,000 shares~~vesting of ~~the Company’s common~~ stock ~~upon receiving the notice to exercise the warrants at an exercise price of $3.50 included in Unit A sold in the private placement held in May 2017, for an aggregate purchase price of $70,000.~~

~~Issuance of Shares for Services~~

options and restricted awards. The ~~Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services.~~ During the nine months ended August 31, 2017, the Company issued an aggregate of 108,705 shares of the Company common stock to various vendors for investor relation and introductory services, valued at approximately $0.5 million based on the estimated fair market value of the stock on the date of grant and$16,000 was recognized within general and administrative expenses in the accompanying ~~Condensed~~ Consolidated ~~Statements~~Statement of Operations for the three ~~and nine~~ months ended ~~August 31, 2017.~~

February 28, 2023.

Issuance of common shares for cash

On February14, 2022, the Company entered into a series of securities purchase agreements for the sale of 400,000 units at a $0.25 unit sales price. The Company raised $100,000 in cash. Each unit consisted of one common share and one warrant to purchase one share of common stock at an exercise price of $0.50. The common warrants issued on February 22, 2022, have a fair value of $0.28 per share, see Note 11.

Issuance of common shares for debt conversion

During the three months ended February 28, 2023, the Company issued 33,823,234 shares of common stock to convert approximately $238,000 of outstanding debt and interest. and extinguished approximately $146,000 of embedded derivative liabilities Additionally, the Company reversed approximately $118,000 of unamortized debt discount upon the conversion.

Note ~~10 –~~11 - Warrants and Options

~~Warrant Liability~~

As of November 30, 2016, the Company had outstanding warrants issued as part of the private placement units initially classified as liabilities because the exercise price may be adjusted downward, in certain circumstances, for a ninety-day period following their initial issuance. Warrant liabilities are measured at fair value, with changes in fair value recognized each reporting period in the Statement of Operations. The warrants ceased being liability classified at the conclusion of the ninetieth day from issuance. As a result, an aggregate of approximately $228,000 in warrant liability was reclassified to equity during the nine months ended August 31, 2017. All other warrants are equity classified.

The warrant liability is a Level 3 fair value measurement, recognized on a recurring basis. Both observable and unobservable inputs may be used to determine the fair value of positions that the Company has classified within the Level 3 category. As a result, the unrealized gains and losses for liabilities within the Level 3 category may include changes in fair value that were attributable to both observable inputs (e.g., changes in market interest rates) and unobservable inputs (e.g., probabilities of the occurrence of an early termination event).

Fair value of warrant liability at November 30, 2016 $ 168,070
Issuance of new warrant liability -
Change in fair value of warrant liability 59,870
Reclassification of warrant liability to equity (227,940 )
Fair value of warrant liability at August 31, 2017 $ -

Summary of warrants

The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at ~~August 31, 2017~~February 28, 2023 and November 30, 2022 and the changes during the period then ~~ended:~~ended (warrants amount and intrinsic value are rounded to nearest thousand):


				Weighted Average
				Remaining
		Weighted Average		Contractual
	Warrants	Exercise Price		Life (years)	Intrinsic Value
Outstanding at November 30, 2022	11,220,000	$	1.01	3.8	$	—
Issued	—		0.50	2.23		—
Forfeited/expired	—		—	—		—
Outstanding and exercisable at February 28, 2023	11,220,000	$	1.01	3.8	$	—

Weighted Average
Weighted Average Remaining Contractual
Warrants Exercise Price Intrinsic Value Life (years)
Outstanding at November 30, 2016 1,047,500 $ 2.54 $ 1,158,000 4.10
Issued 2,006,495 - - -
Exercised (20,000 ) 3.50 - -
Outstanding at August 31, 2017 3,033,995 $ 3.66 $ 1,659,285 4.29
Exercisable at August 31, 2017 2,245,995 $ 3.54 $ 1,617,235 4.19

~~Fair~~

Grant date fair value of all outstanding warrants was ~~calculated with~~based on the following key inputs:


	As of February 28, 2023			As of November 30, 2022
Strike price	$	1.25		$	1.25
Term (years)		5.0			5.0
Volatility		114	%		114	%
Risk-free rate		0.4	%		0.8	%
Dividend yield		0.0	%		0.0	%

	~~For the nine months ended August 31, 2017~~
~~Stock price~~	$	~~3.50 - $7.87~~
~~Term (years)~~		~~1.75 – 5.0~~
~~Volatility~~		~~129.81% - 142.93~~	%
~~Risk-free rate~~		~~1.17% - 1.74~~	%
~~Dividend yield~~		~~0.00~~	%

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Modification date fair value of all outstanding warrants was based on the following key inputs:


	After Modification			Before Modification
Strike price	$	1.77		$	2.51
Term (years)		3.5			0.8
Volatility		123	%		77	%
Risk-free rate		0.5	%		0.4	%
Dividend yield		0.0	%		0.0	%

Warrants issued on February 22, 2022, were classified as liabilities. The fair value of the warrants on grant date was based on the following key inputs:


	February 22, 2022
Strike price	$	0.50
Terms (years)		3.0
Volatility		126	%
Risk-free rate		1.7	%
Dividend yield		0.0	%

Modification of Warrants

On February 1, 2022, the Company modified an aggregate of 245,625 warrants (the “Warrants”) that were originally granted to certain investors and consultants. The exercise price of the Warrants was reduced to $0.65 per share and the maturity dates of the Warrants were extended until August 1, 2024.

The Company received $20,000 cash from one of the investors as consideration for this modification. The Company immediately recognized approximately $17,000 incremental stock-based compensation on February 1, 2022 based on the following weighted average assumptions:


	After Modification			Before Modification
Strike price	$	0.65		$	2.33
Term (years)		2.5			2.1
Volatility		135	%		127	%
Risk-free rate		1.0	%		1.0	%
Dividend yield		0.0	%		0.0	%

Between April and May 2022, the Company modified an aggregate of 4,765,807 warrants (the “Warrants”) that were originally granted to certain investors and officers during 2017 and 2021. The exercise price of the Warrants was reduced to between $0.50 and $0.65 per share and the maturity date of the Warrants were extended for an additional 5 years.

The Company immediately recognized approximately $261,000 incremental stock-based compensation during the quarter ended May 31, 2022 based on the following weighted average assumptions:


	After Modification			Before Modification
Strike price	$	0.51		$	1.76
Term (years)		6.9			2.1
Volatility		118	%		128	%
Risk-free rate		2.7	%		2.2	%
Dividend yield		0.0	%		0.0	%

On August 31, 2022, the Company modified an aggregate of 3,608,641 warrants (the “Warrants”) that were originally granted to certain officers during 2017 and 2021. The exercise price of the Warrants was reduced to $0.10 per share.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

The Company immediately recognized approximately $22,000 incremental stock-based compensation during the quarter ended August 31, 2022 based on the following weighted average assumptions:


	After Modification			Before Modification
Strike price	$	0.10		$	0.50
Term (years)		2.7			2.7
Volatility		151	%		151	%
Risk-free rate		3.5	%		3.5	%
Dividend yield		0.0	%		0.0	%

The new warrants issued in February 2022 and warrant modifications, described above, resulted in reclassifying such modified warrants to purchase an aggregate of 5,461,432 common shares from equity to liability as a result of applying the reassessment under ASC 815. The warrants are subsequently recognized at fair value with changes in fair value recognized in the Company’s Condensed Consolidated Statements of Operations.

Options issued for services

The following represents a summary of all outstanding options to purchase the Company’s common stock at ~~August 31, 2017~~February 28, 2023 and November 30, 2022 and the changes during the period then ~~ended:~~ended (options amount and intrinsic value are rounded to nearest thousand):


				Weighted Average
		Weighted Average		Remaining Contractual
	Options	Exercise Price		Life (years)	Intrinsic Value
Outstanding at November 30, 2022	5,200,000	$	0.10	7.5	$	—
Issued	3,000,000		0.10	5.0		—
Forfeited/expired	—		—	—		—
Outstanding at February 28, 2023	7,450,000	$	0.10	6.5	$	—
Exercisable at February 28, 2023	5,200,000	$	0.10	7.5	$	—

The fair value of options granted on February 28, 2023 was based on the following key inputs:


	February 28, 2023
Strike price	$	0.10
Term (years)		5.0
Volatility		136	%
Risk-free rate		3.3	%
Dividend yield		0.0	%

Weighted Average
Weighted Average Remaining Contractual
Options Exercise Price Intrinsic Value Life (years)
Outstanding at November 30, 2016 - $ - $ - -
Issued 450,000 4.00 26,100 4.76
Exercised - - - -
Outstanding at August 31, 2017 450,000 $ 4.00 $ 26,100 4.76
Exercisable at August 31, 2017 - $ - $ - -

Stock-based Compensation

The Company recognized general and administrative expenses of approximately ~~$4.2 million and $3.0~~$0.02 million as a result of the shares, outstanding warrants and options issued to consultants and employees during the ~~nine~~three months ended February 28, 2022, respectively.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Note 12 – Fair Value Measurements

The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of February 28, 2023 and November 30, 2022 (amounts are rounded to nearest thousand):


	Fair value measured at February 28, 2023
			Quoted prices in active		Significant other		Significant
	Fair value at		markets		observable inputs		unobservable inputs
	February 28, 2023		(Level 1)		(Level 2)		(Level 3)
Embedded derivative liabilities	$	1,434,000	$	—	$	—	$	1,434,000
Derivative liabilities	$	91,000	$	—	$	—	$	91,000


	Fair value measured at November 30, 2022
			Quoted prices in active		Significant other		Significant
	Fair value at		markets		observable inputs		unobservable inputs
	November 30, 2022		(Level 1)		(Level 2)		(Level 3)
Embedded derivative liabilities	$	1,434,000	$	—	$	—	$	1,434,000
Derivative liabilities	$	91,000	$	—	$	—	$	91,000

Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. There were no transfers between levels in the three months ended February 28, 2023.

The Level 1 derivative liability is related to commitment to issue common shares pursuant to the September Debenture which was settled in April 2022 and the August ~~31, 2017~~Debenture which was settled in August 2022 (see Note 7).

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended February 28, 2023. Both observable and ~~2016, respectively.~~

Asunobservable inputs were used to determine the fair value of ~~August 31, 2017,~~positions that the ~~estimated unrecognized stock-based compensation~~Company has classified within the Level 3 category. Unrealized gains and losses associated with ~~these agreements is approximately $3.5 million~~liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and ~~will be recognized over~~unobservable (e.g., changes in unobservable long- dated volatilities) inputs (amounts are rounded to nearest thousand).


	Embedded Derivative		Derivative
	Liabilities		Liabilities
Balance – Level 3, at December 1, 2022	$	1,434,000	$	91,000
Issuance of convertible notes		—		—
Balance – Level 3, at February 28, 2023	$	1,434,000	$	91,000

The fair value of the ~~next 0.32 year.~~contingent put option in all outstanding debentures with the feature and derivative liabilities, comprised of warrant liabilities, are revalued as of February 28, 2023 and November 30, 2022 based on the following weighted average key inputs:


	February 28, 2023						November 30, 2022
	Embedded Derivative			Derivative			Embedded Derivative
	Liabilities			Liabilities			Liabilities
Strike price	$	0.55		$	0.12		$	0.55
Terms (years)		0.3			4.3			0.3
Volatility		200	%		85	%		200	%
Risk-free rate		2.9	%		2.1	%		2.9	%
Dividend yield		0	%		0	%		0	%
Probability factor(1)		20	%		0	%		0	%

(1)The probability factor for DL Note as of February 28, 2023 was 20%.

Table of Contents

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Note 1113 – Subsequent Events

~~Research Agreement #1~~

On ~~September 1, 2017,~~March 31, 2023, the company entered into a 12 month convertible note with an accredited investor in aggregate principal face amount of One Hundred Fifty Thousand Dollars (U.S. $150,000.00) including $15,000.00 original issue discount such that the net receipt was $135,000.00.

On May 26, 2023, the Company ~~entered into~~filed an annual report on Form 10-K and noted that that annual report does not meet fully the ~~research agreement (“Research Agreement #1) with OMRF to have OMRF perform the research program for a maximum period~~requirements of ~~six months. The Company agreed to pay OMRF a total cost of approximately $100,000 for the performance of the research program.~~

~~Conversion of debt~~

~~On October 16, 2017,~~annual reports as required by Form 10-K. Particularly, the Company ~~received~~noted that the ~~conversion notice~~financial statements included in that annual report have not been audited and no audit report regarding such financial statements was included therein. The financial statements included in the annual report are not the type of financial statement that an investor would expect to see from a company that has had its financial statements audited by an independent accounting firm per the ~~holder~~Securities Exchange Act of 1934, as amended, and the ~~Debentures to convert an aggregate of $500,000 in principal of the Second Debenture Note, along with its accrued interest, into an aggregate of 142,662 shares of the Company’s common stock.~~rules and regulations promulgated thereunder. The ~~Company has~~recently filed annual report is unaudited, incomplete and should not ~~issued these shares yet.~~

~~Issuance of securities~~

~~On October 3, 2017,~~be relied upon as accurate, timely or fit for any purpose. Although the Company ~~amended the Debentures~~intends to ~~extend the maturity date from November 30, 2017~~amend that annual report as soon as practicable and invites any inquiries to ~~November 30, 2018, and issued 25,641 restricted shares~~be directed to Company management, it may not be able to ever amend that annual report.

Table of ~~its common stock to the holder of the Debentures as consideration.~~Contents

In September 2017, the Company issued warrants to purchase up to 50,000 shares of the Company’s common stock to two vendors for services. The warrants are exercisable for three years at a per share price of $4.00.

~~Subsequent to August 31, 2017, the Company issued an aggregate of 31,000 shares of its common stock to its vendors for services.~~

Item 2. ~~Management's~~Management’s Discussion and Analysis of Financial Condition and Results of Operation

Forward-Looking Statements

This unreviewed Quarterly Report contains forward-looking statements about our business, financial condition and prospects that reflect management’s assumptions and beliefs based on information currently available. The expectations indicated by such forward-looking statements might not be realized. If any of our management’s assumptions should prove incorrect, or if any of the risks and uncertainties underlying such expectations should materialize, our actual results may differ materially from those indicated by the forward-looking statements.

The key factors that are not within our control and that may have a direct bearing on operating results include, but are not limited to, acceptance of our services, our ability to create and expand our customer base, managements’ ability to raise capital in the future, the retention of key employees and changes in the regulation of our industry.

There may be other risks and circumstances that management may be unable to predict. When used in this Quarterly Report, words such as, ~~"believes," "expects," "intends," "plans," "anticipates," "estimates"~~“believes,” “expects,” “intends,” “plans,” “anticipates,” “estimates” and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.

Overview

Q BioMed Inc. (or “the Company”) was incorporated in the State of Nevada on November 22, 2013 and is a commercial stage biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. We intend to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. We intend to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spin out.

~~On December 7, 2016,~~ Our mission is to solve problems by accelerating the ~~Company formed its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC”~~development of important therapies and availability of those therapies to patients.

Our intent is to monetize the current pipeline and build a platform for future growth. There are 4 areas of focus:.

~~Recent Developments~~

~~On August 1 2017~~ commercial product revenue growth, partnerships, joint venture equity value and future development platform. This quarter has been solely focused on maintaining our pipeline and looking for strategic capital or business partnerships and merger opportunities. The microcap biotechs have all been under pressure and we ~~closed~~are one of many that have a ~~$3,050,390 equity financing. The financing with~~capital requirement that is challenging to service given our debt and current lack of resources. We are determined to find a small group of accredited investors provides the necessary capital to meet near term milestones and catalysts in its most advanced product portfolio assets, including the commercialization of Strontium Chloride 89, multiple IND enabling studies, CMC manufacturing and at least one IND filing.

~~Strontium 89 Chloride commercialization~~

On September 6, 2016, we announced the closing of a definitive agreement to exclusively license worldwide and ultimately acquire all the assets from a private company related to an FDA approved generic drugsolution for the ~~treatment~~benefit of ~~pain associated with metastatic bone~~all our stakeholders.

Commercial Product

We believe that Strontium89 has great potential in the cancer ~~Generic Strontium Chloride Sr-89 Injection USP (“SR89”).~~

This licensed radiopharmaceutical agent is indicated for the treatment of pain associated with metastatic bone cancer. SR89 provides long lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases. It has been proven to provide a long-term effect resulting in non-narcotic cancer pain relief and enhanced quality of life.

We have initiated final drug product manufacturing however as a result of the 2 major hurricanes in both Texas and Florida and their impact on the logistics and in particular the contract manufacturing facilities in those states, we are taking additional steps to ensure that the manufacturing process meets our strict standards and safety is never compromised. We are building additional redundancies into our supply chain, including adding new manufacturing sites and securing the required FDA approval for those sites. We will work with the regulators to affect those changes as soon as possible.palliation space. As a result of ~~these measures SR89 may not~~a world in which opioids were a treatment of choice for those patients unlucky enough to be ~~commercially available until~~diagnosed with painful metastatic cancers in the ~~end~~bone, we felt that Strontium89 had become a neglected and forgotten drug. We have stayed committed to our belief that Strontium89 was a valuable treatment and have focused on advancing that asset from concept, a neglected drug, to a fully approved, reimbursed commercial product. Since we acquired Strontium89, we have built an infrastructure to commercialize the product, including manufacturing, branding, pharmacovigilance, reporting, federal supply contract, and entering into distribution agreements in the United States and several other countries.

Table of ~~2017. A new website, www.PainFreeCancer.com~~Contents

Partnership Opportunities

UTTROSIDE B – Liver Cancer Chemotherapeutic

Along with our developmental partners, we are advancing an innovative treatment for liver cancer, a disease indication that currently has a high unmet need. This molecule was ~~recently announced~~identified in ~~anticipation of the commercial launch.~~

~~We intend~~India, traditionally used to ~~make this drug as widely available as possible and to ensure~~treat liver ailments. Subsequent research on that isolated molecule showed promising data, indicating that the ~~drug will be priced competitively. In light of~~molecule was more cytotoxic, killing cancer cells more effectively, in liver cancer cells lines than the current ~~opiate overuse~~first line liver cancer chemotherapeutic. We have advanced this from a naturally occurring unsustainable plant product to a commercially viable and ~~abuse crisis, we are pleased to be offering this non-narcotic cancer pain palliation~~scalable synthetic drug ~~to patients suffering from this debilitating condition.~~

There are approximately 300,000 new cases of bone metastases in patients with breast and lung cancer per year in the U.S. alone with 1 in 3 of those being ideal candidates for SR89. Approximately 80% of patients using SR89 have reported experiencing a substantial decrease in pain, an increase in physical activity and a reduction in the need for opiate analgesics. In the body, strontium acts similarly to calcium and is preferentially taken up in osteoblastic tissue while the unabsorbed isotope is excreted in the urine the first 2 to 3 days following injection, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

Generic Strontium Chloride Sr-89 Injection USP can be used in combination with (and reduce the dosage of) opiate based drugs like Oxycotin®, Morphine, Percocet® or replace them entirely. It can also be used in combination with cancer therapeutic drugs. Clinical studies have demonstrated that the combination of alternating weekly chemohormonal therapies with SR89 demonstrated a prolonged progression-free and overall survival with acceptable toxicity.

~~We believe there is~~candidate. This provides an opportunity to ~~invest additional resources into the program to grow the revenue potential significantly.~~

~~New License Agreement in Rare Pediatric Autistic Spectrum Disorder~~

~~On April 25, 2017, we entered into~~partner this asset with a licensing agreement that provides us with the worldwide exclusive rights to ASDERA’s ASD-002 (now annotated as QBM-001). QBM-001 is being developed to treat a rare pediatric nonverbal disorder. Under the terms of the agreement, the Company receives global rights to develop and commercialize the drug in the rare pediatric disease market.

We recently announced a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. Sphaera Pharma will employ its proprietary and patented platform to produce a novel analog that aims to reduce or eliminate potential side effects and can reduce the amount of product a toddler needs to take on a daily basis. Preclinical testing of the new analog is currently underway and a final product is scheduled to be ready by the middle of October, putting Q BioMed on a path to file an IND towards the end of 2017 or the beginning of 2018.

The proprietary analog will also allow Q BioMed to apply for a global composition of matter patent for QBM-001, while still ensuring Q BioMed can pursue the 505(b)2 regulatory pathway in the US to ensure toddlers can possibly benefit from QBM-001 as soon as possible.

Among the more than 60,000 US children who develop autism spectrum disorders (ASD) every year, 20,000 become nonverbal or lose the ability to speak. The numbers are similar in Europe and this nonverbal group will have to rely on assisted living for the rest of their life.

Given the severity of this disorder and the immense emotional toll on these children and their families, our goal is to move the product forward quickly by using all the regulatory tools available to us to expedite the advancement of this drug candidate.

The cost for treatment and assisted living in the US alone can equal or exceed ten million dollars per patient over a lifetime. The estimated cost to the US healthcare system and lost productivity is estimated at 200 billion dollars.larger oncology focused institution. Currently, there ~~is no treatment for this disorder. EEG, behavioral,~~are only two approved first-line liver cancer therapies. We have received Orphan Drug Designation, and ~~genetic testing can identify a targeted population of children in their second year of life that we believe would respond to this treatment.~~

Research published in 2014 by Wittkowski et al. in the Nature journal Translational Psychiatry and independently confirmed in 2015 by Guglielmi et al. indicated that certain ion channels were not active enough in this targeted population. Given that we are ~~developing an analogue of a well-known approved drug that regulates these channels, we expect~~now preparing to advance this ~~clinically through a 505(b)2 pathway~~toward clinical partnership. We have been successfully prosecuting our patent portfolio and have received patents or notice of allowance in ~~2018 with a single Phase 2/3 pivotal trial, which, if successful, could have the drug ready for market in less than 2 years.~~

~~New License Agreement in Liver Cancer Chemotherapeutic Drug Candidate~~

~~On June 15, 2017, we signed a final license agreement with The Oklahoma Medical Research Foundation (OMRF)~~several countries including Japan, Canada, USA and ~~the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement Q BioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.~~

~~The compound was isolated and characterized from the leaves of~~ ~~Solanum nigrum~~ Linn, or black nightshade, a plant widely used in traditional medicine. In animal models, the compound, called uttrocide B, was shown to be 10 times more cytotoxic to HepG2 liver cancer cells than the only drug currently on the market for the condition and caused no noticeable side effects.

Liver cancer is the second most common cause of cancer deaths worldwide, according to the Centers for Disease Control and Prevention, and claims approximately 750,000 lives each year. The American Cancer Society estimates that 39,000 people in the U.S. will be diagnosed with primary liver cancer in 2017 and that 27,000 will die from the disease this year.

just recently Europe. We are currently working on synthesizing the molecule chemically to ensure commercial availability and scalability. We anticipate that pre-IND work will be done this year, and the IND is expected to be filed in the first half of 2018.

~~Mannin License Update~~

~~Additionally, Mannin Research Inc. (“Mannin”), our technology partner company focused on drug candidate MAN-01~~looking for treatment of Primary Open Angle Glaucoma (POAG), has initiated pre-clinical lead candidate optimization of a small molecule for topical application. Lead candidate selection is progressing on-time and on-budget. The topical application in the form of an easy to administer eye drop is a key differentiator for Mannin and aims to solve the compliance problems and invasive procedures currently available to patients suffering from glaucoma.

Mannin is continuing its focus on research and discovery on the biology of Tie2/TEK signaling and its relationship with Schlemm’s Canal function and regulation of intra-ocular pressure. Additional data sets and IP have been developed around this novel mechanism of action. Mannin is evaluating strategicclinical partnerships opportunities to grow its intellectual property portfolio within the Tie2/TEK signaling market, and is seeking complementary technologies to strengthen its product pipeline. The Ties/TEK platform is applicable to other indications and we have made progress in identifying potential treatments for cardiovascular diseases as well as kidney diseases using this innovative approach.

In February 2017, Mannin was accepted into Johnson & Johnson Innovation, JLABS @ Toronto. JLABS @ Toronto is a 40,000 square-foot life science innovation center. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS @ Toronto and the companies are free to develop products – either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

Mannin will utilize JLABS @ Toronto as complementary lab space to conduct commercial research and development as it relates to its MAN-01 program for Glaucoma and to the greater Tie2 platform technology. As a resident, Mannin will have access to the development and commercialization expertise provided by JLABS @ Toronto. Mannin has been utilizing its presence in JLABS @Toronto to increase its visibility within the biotechnology community in Toronto. Since taking up residency in JLABS in January 2017, Mannin has participated in numerous events hosted at the JLABS @ Toronto site. These events have provided Mannin with one-on-one interactions with investors, media, government agencies, and industry executives. Being a JLABS resident company provides Mannin with access to a world class network of investors and industry partners. Mannin is establishing research and development partnerships with companies and organizations to provide direct support for the MAN-01 program and Mannin’s other research and development initiatives.

Mannin Research will be presenting at Spotlight on JLABS, at JLABS @ Toronto on Wednesday October 11th. Spotlight provides the opportunity to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in Toronto. Mannin is one of four companies that will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS.

Mannin Research Inc. will also attend the JLABS CEO Summit on Wednesday October 18th and 19th in San Diego, California. The JLABS CEO Summit provides resident companies at any of the JLABS sites to come together for networking, workshops & seminars, and 1:1 meetings with investors, other JLABS residents, or their JPAL mentor. The goal of the program is to provide JLABS residents with a forum to explore potential areas of partnership with J&J.

~~We are pleased with the progress Mannin research teams have achieved over the past several months.~~

We continue to advance all the assets in our pipeline. We have executed on our plan to build a pipeline of considerable inherent value with several catalysts expected for the duration of 2017 and into 2018. We aim to have a commercial drug on the market by the end of 2017and at least 2 new INDs filed in 2018 including a Phase 4 and a Phase 2/3 pivotal trial. We remain committed to advancing our assetsthis product towards the patients that need ~~them.~~

it.

Development Platform - Rare Disease Focus

During 2023 we will focus our future development platform on the Rare Disease Space. This focuses our resources on an area in which we already have a presence. Our liver cancer drug candidate, Uttroside B, has already received Orphan Drug Designation. We expect to partner this asset in 2023 and will grow our development platform through in-licensing or acquisition once we have the capital to do so.

This rare disease platform will also complement our early-stage treatment for young minimally verbal children on the Autism Spectrum.

Corporate Strategic Goals

Our mission is to solve problems by accelerating the development of important therapies and the availability of those therapies to patients. We have been busy building a portfolio that we believe has significant value ranging from blockbuster potential drugs to revenue-producing opportunities. Lack of capital is our rate limiting factor and we are engaging in efforts along with our bankers and consultants to find both capital and strategic opportunities to unlock the potential in our pipeline.

Financial Overview

~~Off-Balance Sheet Arrangements~~

~~We do not have any off-balance sheet arrangements.~~

Critical Accounting Policies and Estimates

~~This~~

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities inat the date of our condensed consolidated financial ~~statements. On an ongoing basis, we evaluate~~statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our ~~estimates and judgments, including those related to fair value of financial instruments, research and development costs, accrued expenses and stock-based compensation. We base our estimates on~~ historical experience ~~known trends~~ and ~~events and~~on various other factors that we believe ~~to be~~are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying ~~values~~value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or ~~conditions.~~conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates. Other than as set out in Note 3 to our accompanying unaudited condensed consolidated financial statements, if anything, we believe there have been no significant changes in our critical accounting policies as described in the Form 10-K.

Table of Contents

Unaudited Results of Operations for the three months ended ~~August 31, 2017~~February 28, 2023 and ~~2016:~~2022:


	For the Three Months Ended
	February 28, 2023		February 28, 2022		Change
Net Sales	$	—	$	75,059	$	(75,059)
Cost of sales		2,500		73,945		(71,445)
Gross income (loss)		(2,500)		1,114		(3,614)
Operating expenses:
General and administrative expenses		439,818		1,096,300		(656,482)
Research and development expenses		2,691		69,268		(66,577)
Total operating expenses		442,510		1,165,568		(723,058)
Loss from operations		(445,010)		(1,164,454)		719,444
Other (income) expenses:
Interest expense		276,602		414,377		(137,775)
Change in fair value of derivatives		—		235,817		(235,817)
Loss on debt extinguishment		—		232,100		(232,100)
Settlement of registration liability		—		241,875		(241,875)
Total other expenses (income)		276,602		1,124,169		(847,567)
Net loss		(721,612)		(2,288,623)		1,772,142
Accumulated dividend on convertible preferred stock		(104,800)		(122,808)		18,008
Net loss attributable to common stockholders	$	(826,412)	$	(2,411,431)	$	1,585,019

For the three months ended August 31,
2017 2016
Operating expenses:
General and administrative expenses $ 3,038,018 $ 1,150,964
Research and development expenses 697,966 443,222
Total operating expenses 3,735,984 1,594,186

Other income (expenses):
Interest expense (202,160 ) (114,847 )
Interest income 15 -
Loss on conversion of debt - (29,032 )
Loss on extinguishment of debt (76,251 ) -
Loss on issuance of convertible notes - (28,000 )
Change in fair value of embedded conversion option 32,983 50,000
Change in fair value of warrant liability - -
Total other expenses (245,413 ) (121,879 )

Net loss $ (3,981,397 ) $ (1,716,065 )

Net Sales

During the three months ended February 28, 2023 and 2022, we recognized approximately no sales and $75,000, respectively, of revenue from sales of Strontium89. The decrease was due to less vials were sold during the three months ended February 28, 2023 compared to the same period in the prior year.

Cost of Sales

During the three months ended February 28, 2023 and 2022, we recognized approximately 3,000 and $74,000, respectively, in cost of sales. These costs were related to raw materials cost, manufacturing cost, handling cost and write-offs of expired inventory.

Operating expenses

We incur various costs and expenses in the execution of our business. The ~~increase~~decrease in operating expenses was mainly due to ~~more~~a lower burn and scaled back operations due to lack of available capital. We had an approximate $62,000 less costs from marketing, $465,000 less costs from legal and other professional ~~fees incurred in connection with the license agreements with Mannin, BNI and Asdera as well as the issuance and conversion of convertible notes.~~

~~Other expenses~~

~~During~~services during the three months ended ~~August 31, 2017, other expenses included approximately $202,000~~February 28, 2023 compared to the same period in the prior year.

Interest expense

The following table summarizes interest expense ~~a gain~~incurred during the three months ended February 28, 2023 and 2022, respectively (amounts are rounded to nearest thousand):


	For the Three Months Ended
	February 28, 2023		February 28, 2022
Interest expense based on the coupon interest rate of the outstanding debt	$	51,000	$	61,000
Accretion of debt discount		217,000		352,000
Other		9,000		1,000
Total interest expense	$	277,000	$	414,000

Table of ~~$33,000 for~~Contents

Change in fair value of embedded derivatives

We recognized loss of approximately $236,000 resulting from the change in fair value of embedded contingent put options in convertible notes during the three months ended February 28, 2022, respectively. The fluctuation is mainly due to the change in stock price during the reporting periods.

Loss on debt extinguishment

We recognized a loss of approximately $232,000 due to the conversion ~~options, approximately $76,000 in~~of outstanding debentures into shares of common stock during the three months ended February 28, 2022, respectively.

Net loss ~~on the extinguishment of debt.~~

During the three months ended August 31, 2016, other expenses included approximately $115,000 in interest expense, a gain of $50,000 for the change in fair value of embedded conversion options, $28,000 in loss on the issuance of convertible debt,February 28, 2023 and ~~$29,000 in loss on conversion of debt.~~

~~The increase in other expenses were mainly due to the loss in extinguishment of debt and less gain in change in fair value of embedded conversion option.~~

~~Net loss~~

~~In the three months ended August 31, 2017 and 2016,~~2022, we incurred net losses of approximately $4$0.7 million and ~~$1.7~~$2.3 million, respectively. Our management expects to continue to incur net losses for the foreseeable future, due to our need to continue to establish a broader pipeline of assets, expenditure on R&D and to implement other aspects of our business plan.

~~Unaudited Results of Operations for the nine months ended August 31, 2017 and 2016:~~

For the nine months ended August 31,
2017 2016
Operating expenses:
General and administrative expenses $ 6,122,565 $ 3,637,868
Research and development expenses 2,296,324 663,500
Total operating expenses 8,418,889 4,301,368

Other income (expenses):
Interest expense (635,267 ) (304,596 )
Interest income 123 -
Loss on conversion of debt (365,373 ) (89,210 )
Loss on extinguishment of debt (76,251 ) -
Loss on issuance of convertible notes - (481,000 )
Change in fair value of embedded conversion option (812,017 ) 362,000
Change in fair value of warrant liability (59,870 ) -
Total other expenses (1,948,655 ) (512,806 )

Net loss $ (10,367,544 ) $ (4,814,174 )

~~Operating expenses~~

We incur various costs and expenses in the execution of our business. The increase in operating expenses was mainly due to more professional fees incurred in connection with the license agreements with Mannin, BNI and Asdera as well as the issuance and conversion of convertible notes.

~~Other expenses~~

During the nine months ended August 31, 2017, other expenses included approximately $635,000 in interest expense, $812,000 for the change in fair value of embedded conversion options, approximately $60,000 for the change in fair value of warrant liability, $76,000 in loss on extinguishment of debt, and approximately $365,000 in loss on conversion of debt. During the nine months ended August 31, 2016, other expenses included approximately $305,000 in interest expense, a gain of $362,000 for the change in fair value of embedded conversion options, $481,000 in loss on the issuance of convertible debt, and approximately $89,000 in loss on conversion of debt.

~~The increase in other expenses were mainly due to interest expense and the change in fair value of embedded conversion option.~~

~~Net loss~~

In the nine months ended August 31, 2017 and 2016, we incurred net losses of approximately $10.4 million and $4.8 million, respectively. Our management expects to continue to incur net losses for the foreseeable future, due to our need to continue to establish a base of operations and implement other aspects of our business plan.

Liquidity and Capital Resources

We prepared the accompanying ~~condensed~~ consolidated financial statements assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

We have not yet established ana significant ongoing source of revenues ~~sufficient to~~and must cover our operating ~~costs~~through debt and equity financings to allow us to continue as a going concern. We had approximately ~~$2.5 million~~$23,000 in cash as of ~~August 31, 2017.~~February 28, 2023. Our ability to continue as a going concern depends on ~~the~~our ability to obtain adequate capital to fund operating losses until we generate adequate cash flows from operations to fund ~~its~~our operating costs and obligations. If we are unable to obtain adequate capital, we could be forced to cease operations.

We depend upon our ability, and will continue to attempt, to secure equity and/or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our management ~~has~~ determined that there iswas substantial doubt about our ability to continue as a going concern within one year after the ~~condensed~~ consolidated financial statements ~~are issued.~~

were issued, and management’s concerns about our ability to continue as a going concern within the year following this report persist.

The accompanying ~~condensed~~ consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods addressed in this report:


	For the Three Months Ended
	February 28, 2023		February 28, 2022
Net Cash provided by (used in)
Operating activities	$	(138,187)	$	(376,856)
Investing activities		—		—
Financing Activities		111,387		170,030
Net increase (decrease) in cash		(26,800)		(206,826)

For the nine months ended August 31,
2017 2016

Net cash (used in) provided by:
Operating activities $ (3,923,455 ) $ (868,497 )
Financing acitivities 4,953,900 875,075
Net (decrease) increase in cash $ 1,030,445 $ 6,578

Net ~~cash used in~~Cash Provided by (Used in) Operating Activities

During the three months ended February 28, 2023, operating activities ~~was approximately $4~~used $0.1 million ~~for the nine months ended August 31, 2017 as compared to approximately $869,000 for the nine months ended August 31, 2016. The increase in net~~of cash, ~~used in operating activities relates to the~~resulting from a net loss of ~~approximately $10.4~~$0.7 million, ~~for the nine months ended August 31, 2017,~~ partially offset by ~~aggregate~~$0.02 million of share-based compensation, and non-cash ~~expenses~~interest expense resulting from accretion of debt discounts of $0.02 million and changes in our operating assets and liabilities of approximately ~~$6.4~~$0.4 million. ~~The net cash used in~~

Table of Contents

During the three months ended February 28, 2022, operating activities ~~for the nine months ended August 31, 2016 relates to the~~used $0.4 million of cash, resulting from a net loss of ~~approximately $4.8~~$2.3 million, ~~for the nine months ended August 31, 2016,~~ partially offset by ~~aggregate non-cash expenses~~$0.2 million of share-based compensation, change in fair value of embedded conversion options of $0.2 million, settlement on registration liability of approximately ~~$3.5~~$0.2 million, loss on debt extinguishment of approximately $0.2 million, and non-cash interest expense resulting from accretion of debt discounts of $0.4 million and changes in our operating assets and liabilities of approximately $0.7 million.

Net Cash Provided by (Used in) Investing Activities

During the three months ended February 28, 2023, there were no cash activity related to investing.

During the three months ended February 28, 2022, there were no cash activity related to investing.

Net Cash (Used in) Provided by Financing Activities

Net cash provided by financing activities ~~was approximately $5 million~~ for the ~~nine~~three months ended ~~August 31, 2017, resulting mainly from~~February 28, 2023 was $0.1 million. The net cash provided in the 2023 period relates to proceeds received from the issuance of convertible ~~notes payable and private placement.~~ notes.

Net cash provided by financing activities ~~was $875,000~~ for the ~~nine~~three months ended ~~August 31, 2016, resulting mainly from~~February 28, 2022 was $0.2 million. The net cash provided in the 2022 period relates to proceeds received from the issuance of ~~convertible notes payable.~~

~~Commitments~~common stock and ~~Contingencies~~

warrant, warrants modification and cash advances.

Obligations and Commitments

Legal

Periodically, we review the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, we accrue a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation.

Advisory Agreements

We entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which we agreed to issue shares of common stock as services are received.

Lease Agreement

In December 2016, we entered into a lease agreement for office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ended in December 2019 and has been further renewed in 2023 for another three years, at a reduced rate of $15000 per year. This agreement does not identify a specific asset and does not convey the use of substantially all of the shared office capacity. As such, this agreement does not contain a lease under ASC 842. We recognize monthly license payments as incurred over the term of the arrangement.

Rent expense is classified within general and administrative expenses on a straight-line basis.

License Agreements

Mannin

On October 29, 2015, we entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby we were granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License. Pursuant to the exclusive license from Mannin, we may purchase the Mannin IP within six years of entry into the agreement. During the

Table of Contents

three months ended Fe, we respectively incurred approximately $0.8 million and $1.0 million of research and development expenses under our license with Mannin. The purchase option under the license agreement has now expired.

On March 26, 2019, we entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021 in exchange for our issuing 100,000 shares to Mannin Research Inc. on April 9, 2019.

On September 1, 2020, we further amended the license agreement allowing Mannin to grant an exclusive license to Mannin GmbH (its wholly owned German subsidiary) in order fully take advantage of the German government grant to Mannin. The agreement also confirms our ongoing investment into the Tie2 platform to create, and therefore maintain economic value for us and our shareholders. We have agreed to contribute funds in Mannin GmbH. We paid Mannin $1.5 million in cash payable in three instalments. In addition, we paid to Mannin $0.75 million in shares of our common stock valued as ~~disclosed~~of June 15, 2020, in full satisfaction of R&D payables, contracted by Mannin in development of the Tie2 platform. We continue to have the right to 100% of the revenues derived from the Mannin Tie2 technology platform, until such time that Mannin and its subsidiaries have independently raised at least $2 million in funds, expected to happen in 2022, at which time the parties have agreed to a profit share structure reducing our ~~Annual Form 10-K, filed with~~future capital commitments to Mannin R&D.

During the ~~SEC on~~period ended February 28, ~~2017, during~~2023 and year ended November 30, 2022, the ~~three and nine months ended August 31, 2017, we~~Company incurred approximately ~~$525,000~~$0.0 and ~~$1.4~~$0.1 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the ~~Patent and Technology License and Purchase Option Agreement (“Exclusive License”). Through August 31, 2017, we have funded an aggregate of $2.15 million to Mannin under the~~ Exclusive License.

~~Bio-Nucleonics~~

Washington University

On ~~September 6, 2016, we~~March 9, 2019, the Company entered into ~~the Patent and Technology~~an Exclusive License ~~and Purchase Option~~ Agreement with ~~Bio-Nucleonics Inc. (“BNI”) whereby we were granted~~Washington University for license of a ~~worldwide, exclusive, perpetual, license on, and option~~diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15. The agreement calls for the Company to ~~acquire certain BNI intellectual property (“BNI IP”) within the three-year term of the Exclusive License.~~

During the three and nine months ended August 31, 2017, we incurred approximately $144,000 and $352,500, respectively, in research and development expenses pursuant to the Exclusive License with BNI. As of August 31, 2017, we had paid approximately $351,700 to BNI out of the $850,000 cash funding requirement. We are not obligated to provide further funding to BNI until BNI satisfies all of its pre-existing obligations totaling $163,500. To this end, we had providedpay an ~~aggregate~~initial fee of approximately ~~$59,000 through August 31, 2017~~$88,000, pay annual maintenance fees ranging from $15,000 to ~~BNI to help settle its obligations, which we recognized as research and development expenses in the accompanying Statements of Operations.~~

~~Asdera~~

On April 21, 2017, we entered into a License Agreement on Patent & Know-How Technology (“Asdera License”) with Asdera LLC (“Asdera”) whereby we were granted a worldwide, exclusive, license on certain Asdera intellectual property (“Asdera IP”). The initial cost to acquire the Asdera License is $50,000 and the issuance of 125,000 shares of our common stock, with a fair value of $487,500, of which we had fully paid and issued as of August 31, 2017. In addition to royalties based upon net sales of the product candidate, if any, we are required to make certain additional payments upon the following milestones:

	~~the filing of an investigational new drug application (the “IND”) with the US Food and Drug Administration (“FDA”);~~

	~~successful interim results of Phase II/III clinical trial of the product candidate;~~

	~~FDA acceptance of a new drug application;~~

	~~FDA approval of the product candidate; and~~

	~~achieving certain worldwide net sales.~~

Subject to the terms of the Agreement, we will be in control of the development and commercialization of the product candidate and are responsible for the costs of such development and commercialization. We have undertaken a good-faith commitment to (i) initiate a Phase II/III clinical trial at the earlier of the two-year anniversary of the agreement or one year from the FDA’s approval of the IND and (ii) to make the first commercial sale by the fifth-anniversary of the agreement. Failure to show a good-faith effort to meet those goals would mean that the Asdera IP would revert to Asdera. Upon such reversion, Asdera would be obligated to pay us royalties on any sales of products derived from the Asdera IP until such time that Asdera has paid us twice the sum that we had provided Asdera prior to the reversion.

~~OMRF~~

~~OMRF License Agreement~~

~~On June 15, 2017, we entered into a Technology License Agreement (“OMRF~~ License Agreement”) with the Rajiv Gandhi Centre for Biotechnology, an autonomous research institute under the Government of India (“RGCB”), and the Oklahoma Medical Research Foundation (“OMRF” and together with RGCB, the “Licensors”), whereby the Licensors granted us a worldwide, exclusive, license on intellectual property related to Uttroside B (the “Uttroside B IP”). Uttroside B is a chemical compound derived from the plant ~~Solanum nigrum Linn, also known as Black Nightshade or Makoi. We seek to use the Uttroside B IP to create a~~ ~~chemotherapeutic agent against liver cancer.~~

~~The initial cost to acquire the~~ ~~OMRF~~ ~~License Agreement is $10,000. In addition to royalties based upon net sales of the product candidate, if any, we are required to~~$75,000, make additional payments upon the following milestones:



~~the completion~~●

The first commercial sale of ~~certain preclinical studies (the “Pre-Clinical Trials”);~~a companion diagnostic product;



~~the filing~~●

	~~successful completion of each of Phase I, Phase II and Phase III clinical trials;~~

●	~~FDA approval of the product candidate;~~

	PMA or 510(k) regulatory approval by the FDA or the foreign ~~equivalent of the FDA of the product candidate;~~

	~~achieving certain worldwide net sales;~~equivalent; and



●

The first commercial sale of a ~~change of control of QBIO.~~diagnostic product.

~~Subject~~

In addition to the ~~terms~~above payments, royalty payments based upon sales of ~~the Agreement, we will be in control of the development and commercialization of the~~a companion diagnostic product ~~candidate and~~or diagnostic product are responsible for the costs of such development and commercialization. We have undertaken a good-faith commitment to (i) fund the Pre-Clinical Trials and (ii) to initiate a Phase II clinical trial within six years of the date of the Agreement. Failure to show a good-faith effort to meet those goals would mean that the ~~OMRF~~ ~~License Agreement would revert to the Licensors.~~

~~Milestones~~

~~No milestones have been reached to date on these license agreements.~~

required.

Related Party Transactions

We entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were approximately $102,500 and $104,000 for the three months ended August 31, 2017 and 2016, respectively, and were approximately $322,500 and $207,875 for the nine months ended August 31, 2017 and 2016, respectively, included within general and administrative expenses in the accompanying Condensed Consolidated Statements of ~~Operations.~~Operations as follows (amounts are rounded to nearest thousand):

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Table of Contents

Item 3. Quantitative and Qualitative Disclosure About Market Risk

~~This item is not applicable as we~~

We are ~~currently considered~~ a smaller reporting ~~company.~~

company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

~~Our Principal Executive Officer and Chief Financial Officer evaluated the effectiveness of our~~

Management is required to maintain disclosure controls and procedures ~~(as defined~~that are designed to ensure that information required to be disclosed in ~~Rule 13a-15(e)~~our reports, filed under the Exchange Act) as of the period covered by this Report. Based on that evaluation, it was concluded that our disclosure controls and procedures are not effective to reasonably assure that information we are required to disclose in the reports that we file or submit under theSecurities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our ~~principal~~chief executive officer and ~~principal~~chief financial officer, ~~or persons performing similar functions,~~ as appropriate, to allow timely decisions regarding required disclosure.

~~We do~~ In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not ~~have~~absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by the SEC Rules 13a-15(b) and 15d-15(b), an ~~Audit Committee; our board of directors currently acts as our Audit Committee. We do not have an independent director,~~evaluation is required to be carried out under the supervision and ~~none~~with the participation of our ~~directors is considered a “Financial Expert,” within the meaning of Section 407~~management, including our principal executive officer and principal financial officer, of the ~~Sarbanes-Oxley Act. We have interviewed several potential independent directors, but have~~effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below:

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible, however segregation of duties has been implemented, with regards to the initiation of transactions, the custody of assets and the recording of transactions performed by separate individuals.

2.	We do not have in-house personnel with sufficient experience with United States generally accepted accounting principles to address complex transactions. These functions have been outsourced.

3.	We have determined that oversight over our external financial reporting and internal control over our financial reporting is ineffective as we do not have an audit committee in place.

4.	We have not had our independent accountants audit our financial statements for the year ended November 30, 2022 and provide us with a report for such audit.

5.	We have not had our independent accountants review our financial statements for the three months ended February 28, 2023.

To address these material weaknesses, management engaged ~~any.~~financial consultants, performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

Table of Contents

Changes in internal controls over financial reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. We plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects. We have engaged accounting and compliance consultants to review our internal controls over financial reporting and other compliance requirements.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

As previously reported, on July 12, 2022 the Company was notified that WSI PBG, LLC (“WSI”) filed a complaint against the Company seeking to recover $196,216 in unpaid consulting fees, plus costs and expenses of litigation. The Company elected not to litigate this suit so as not to increase its liability exposure. Not unexpectedly, on August 24, 2022, WSI obtained a judgment against the Company in the amount of $203,784. The Company is exploring its options in addressing this judgment, including terms of settlement that would result in a satisfaction of this Judgment over a limited period of time.

On July 19, 2022, we received notice that the Activus Group (“Activus”) filed a complaint for fees it alleges are due in the amount $129,600 plus fees and expenses for consulting services provided by Activus as a result of an agreement between the parties. We have not filed an answer and are currently determining our next steps in settlement.

result of the foregoing, DHS obtained a default judgment against the Company in the amount of $111,000. The company is exploring its options in addressing this judgment, including terms of settlement that would result in a satisfy of this Judgment over a limited period of time.

Item 1A. Risk Factors

~~As a Smaller Reporting Company, we~~

Although risk factors are not required for smaller reporting companies, we stress the following risk:

We note that neither this quarterly report on Form 10-Q (“Quarterly Report”) nor our annual report on Form 10-K for the year ended November 30, 2022 (“Annual Report”) fully meets the requirements of their respective forms. Particularly, we note that the financial statements included in the Annual Report were not audited and no audit report regarding such financial statements was included therein. Additionally, we note that the financial statements included in the Quarterly Report have not been reviewed and approved by an independent public accounting firm. Although we believe that the financial statements in the Annual Report and Quarterly Report satisfy the current public information requirements of Rule 144(c)(2), the financial statements in the Annual Report are not the type of financial statements that an investor would expect to ~~provide~~see from a company that has had its financial statements audited by an independent public accounting firm per the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder and the financial statements in the Quarterly Report are not the type of financial statements that an investor would expect to see from a company that has had its financial statements reviewed by an independent public accounting firm per the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. Neither the Annual Report nor the Quarterly Report is complete and neither should not be relied upon as accurate, timely or fit for any purpose. Although the Company intends to amend its Annual Report and this ~~information.~~

Quarterly Report as soon as practicable and invites any inquiries to be directed to Company management, it may not be able to ever amend the Annual Report or this Quarterly Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On ~~August 1, 2017,~~December 12, 2022 we issued ~~an aggregate of 953,249 units to third-party investors in a private placement, with each unit consisting~~ ~~one common stock and one warrant exercisable for five years from the date of issuance into a share of the Company’s common stock at an exercise price of $4.50.~~

~~On October 3, 2017, we issued 25,641 restricted~~4,077,094 shares of ~~our~~ common stock ~~to the holder of the Debentures as consideration for extending the maturity date of the Debentures from November 30, 2017 to November 30, 2018.~~

~~In September and October 2017, we issued an aggregate of 31,000 shares of its common stock to our vendors for services.~~

~~On October 16, 2017, we issued 146,662 shares of our common stock to the holder of a convertible notes issued on March 10, 2017~~ upon the conversion of ~~$500,445.21~~$44,348 of ~~principal~~convertible notes and ~~interest~~accrued interest.

On December 2, 2022 we issued 3,564,832 shares of ~~such note.~~common stock upon the conversion of $39,569 of convertible notes and accrued interest.

On January 4, 2023 we issued 2,817,039 shares of common stock upon the conversion of $26,769 of convertible notes and accrued interest.

On January 6, 2023 we issued 3,048,780 shares of common stock upon the conversion of $25,000 of convertible notes and accrued interest.

Table of Contents

On January 13, 2023 we issued ~~these~~3,174,603 shares ~~in reliance on exemptions from registration under Section 4(2)~~of common stock upon the conversion of $20,000 of convertible notes and accrued interest.

On January 20, 2023 we issued 4,679,501 shares of common stock upon the conversion of $32,288 of convertible notes and accrued interest.

On January 24, 2023 we issued 4,111,8429 shares of common stock upon the conversion of $25,082 of convertible notes and accrued interest.

On January 26, 2023 we issued 5,084,746 shares of common stock upon the conversion of $30,000 of convertible notes and accrued interest.

On February 3, 2023 we issued 4,540,772 shares of common stock upon the conversion of $25,882 of convertible notes and accrued interest.

On February 7, 2023 we issued 2,639,237 shares of common stock upon the conversion of $16,100 of convertible notes and accrued interest.

On February 13, 2023 we issued 5,869,163 shares of common stock upon the conversion of $27,000 of convertible notes and accrued interest.

On February 13, 2023 we issued 5,982,513 shares of common stock upon the conversion of $32,305 of convertible notes and accrued interest.

On February 14, 2023 we issued 5,212,174 shares of common stock upon the conversion of $24,000 of convertible notes and accrued interest.

On February 22, 2023 we issued 4,964,194 shares of common stock upon the conversion of $18,860 of convertible notes and accrued interest.

The issuance of the Securities ~~Act~~mentioned above, if any, qualified for the exemption from registration continued in section 4(a) of ~~1933, as amended. We have previously reported all other sales~~the securities act of ~~unregistered securities otherwise required to be included in this section.~~

1933.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

~~None.~~

Item 6. Exhibits

Exhibit Number		Name and/or Identification of Exhibit
101
~~31.1~~	~~Rule 13a-14(a)/15d-14(a) Certifications~~

~~32.1~~	~~Certification under Section 906 of the Sarbanes-Oxley Act (18 U.S.C. Section 1350)~~

~~101~~	Interactive Data File
101.INS
~~101.INS~~	Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

Table of Contents

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Q BIOMED INC.

~~October 18, 2017~~ Dated: June 16, 2023	By:	/s/ Denis Corin
		Denis Corin
		President, Chief Executive Officer, Acting Principal Accounting Officer, Principal Financial Officer

Nevada	30-0967746

~~[X]~~	~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~
~~For the quarterly period ended: August 31, 2017~~

or

~~[ ]~~	~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~
~~For the transition period from ____________ to _____________~~

~~Commission File Number:~~ ~~000-55535~~

~~Q BIOMED INC.~~
~~(Exact name of registrant as specified in its charter)~~

~~Nevada~~		~~46-4013793~~
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

c/o Ortoli Rosenstadt LLP ~~501~~ 366 Madison ~~Ave. 14th~~Avenue, 3rd Floor New York, ~~NY10022~~ NY 10017
(Address of principal executive offices)

(212) 588-0022
(~~Registrant's~~Registrant’s telephone number, including area code)


Large accelerated filer☐			Accelerated filer	☐
Non-accelerated filer☒		~~(Do not check if smaller reporting company)~~	Smaller reporting company	☒
			Emerging growth company	☐


Common Stock, $0.001 par value	~~11,695,472~~ 145,094,531 shares
(Class)	(Outstanding as at ~~October 17, 2017)~~June 15, 2023)


Title of each class	Symbol	Name of each exchange on which registered
None	None	None


	Page
PART I –- FINANCIAL INFORMATION		2	1
Item 1. Condensed Consolidated Financial Statements (Unaudited)		2	1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16	23
Item 3. Quantitative and Qualitative Disclosure About Market Risk		23	29
Item 4. Controls and Procedures		23	29
PART II –- OTHER INFORMATION		24	31
Item 1. Legal Proceedings		24	31
Item 1A. Risk Factors		24	31
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		24	31
Item 3. Defaults Upon Senior Securities		24	32
Item 4. Mine Safety Disclosures		24	32
Item 5. Other Information		24	32
Item 6. Exhibits		24	33
SIGNATURES		25	34

	August 31, 2017			November 30, 2016
	(Unaudited)
ASSETS
Current assets:
Cash	$	2,499,169		$	1,468,724
Prepaid expenses		5,000			-
Total current assets		2,504,169			1,468,724
Total Assets	$	2,504,169		$	1,468,724

LIABILITIES AND STOCKHOLDERS' EQUITY DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	382,055		$	497,936
Accrued expenses - related party		17,500			70,502
Accrued interest payable		33,299			48,813
Convertible notes payable (See Note 5)		1,922,474			2,394,849
Note payable		138,856			100,152
Warrant liability		-			168,070
Total current liabilities		2,494,184			3,280,322

Long-term liabilities:
Convertible notes payable (See Note 5)		-			231,517
Total long term liabilities		-			231,517
Total Liabilities		2,494,184			3,511,839

Commitments and Contingencies (Note 6)

Stockholders' Equity Deficit:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of August 31, 2017 and November 30, 2016		-			-
Common stock, $0.001 par value; 250,000,000 shares authorized; 11,496,169 and 9,231,560 shares issued and outstanding as of August 31, 2017 and November 30, 2016, respectively		11,496			9,231
Additional paid-in capital		18,667,736			6,249,357
Accumulated deficit		(18,669,247	)		(8,301,703	)
Total Stockholders' Equity Deficit		9,985			(2,043,115	)
Total Liabilities and Stockholders' Equity Deficit	$	2,504,169		$	1,468,724
The accompanying notes are an integral part of these condensed consolidated financial statements

	For the three months ended August 31,						For the nine months ended August 31,
	2017			2016			2017			2016
Operating expenses:
General and administrative expenses	$	3,038,018		$	1,150,964		$	6,122,565		$	3,637,868
Research and development expenses		697,966			443,222			2,296,324			663,500
Total operating expenses		3,735,984			1,594,186			8,418,889			4,301,368

Other income (expenses):
Interest expense		(202,160	)		(114,847	)		(635,267	)		(304,596	)
Interest income		15			-			123			-
Loss on conversion of debt		-			(29,032	)		(365,373	)		(89,210	)
Loss on extinguishment of debt		(76,251	)		-			(76,251	)		-
Loss on issuance of convertible notes		-			(28,000	)		-			(481,000	)
Change in fair value of embedded conversion option		32,983			50,000			(812,017	)		362,000
Change in fair value of warrant liability		-			-			(59,870	)		-
Total other expenses		(245,413	)		(121,879	)		(1,948,655	)		(512,806	)

Net loss	$	(3,981,397	)	$	(1,716,065	)	$	(10,367,544	)	$	(4,814,174	)

Net loss per share - basic and diluted	$	(0.37	)	$	(0.19	)	$	(1.03	)	$	(0.55	)

Weighted average shares outstanding, basic and diluted		10,816,282			8,909,414			10,074,766			8,784,373

Potentially dilutive securities	August 31, 2017		August 31, 2016
Warrants (Note 10)		3,033,995		976,500
Convertible debt (Note 5)		567,407		506,757

	August 31, 2017			November 30, 2016
Series A Notes:
Principal value of 10%, convertible at $2.00 at November 30, 2016.	$	-		$	12,500
Fair value of bifurcated embedded conversion option of Series A Notes		-			12,000
Debt discount		-			(2,194	)
Carrying value of Series A Notes		-			22,306

Series B Notes:
Principal value of 10%, convertible at $2.00 at November 30, 2016.		-			55,000
Fair value of bifurcated embedded conversion option of Series B Notes		-			55,000
Debt discount		-			(19,229	)
Carrying value of Series B Notes		-			90,771

Series C Notes:
Principal value of 10%, convertible at $1.55 at November 30, 2016.		-			576,383
Fair value of bifurcated embedded conversion option of Series C Notes		-			838,000
Debt discount		-			(250,969	)
Carrying value of Series C Notes		-			1,163,414

Series D Notes:
Principal value of 10%, convertible at $1.85 at November 30, 2016.		-			160,000
Debt discount		-			(140,961	)
Carrying value of Series D Notes		-			19,039

Series E Notes:
Principal value of 10%, convertible at $2.50 at August 31, 2017 and November 30, 2016.		30,000			180,000
Debt discount		(4,062	)		(124,164	)
Carrying value of Series E Notes		25,938			55,836

Convertible Debenture:
Principal value of 5%, convertible at $3.60 and $2.98 at August 31, 2017 and November 30, 2016, respectively.		2,000,000			1,500,000
Fair value of bifurcated contingent put option of Secured Convertible Debenture		2,000			72,000
Debt discount		(105,464	)		(297,000	)
Carrying value of Secured Convertible Debenture Note		1,896,536			1,275,000
Total short-term carrying value of convertible notes	$	1,922,474		$	2,394,849
Total long-term carrying value of convertible notes	$	-		$	231,517

Rollforward of Level 3 Fair Value Measurement for the Nine Months Ended August 31, 2017

Balance at November 30, 2016			Issuance		Net unrealized gain/(loss)		Conversion			Balance at August 31, 2017
	$	977,000		86,000		812,017		(1,873,017	)		$	2,000

	Principal		Shares
Series A conversions		12,500		5,936
Series B conversions		55,000		27,995
Series C conversions		576,383		407,484
Series D conversions		160,000		91,782
Series E conversions		150,000		63,255
Secured Debenture conversions		2,000,000		461,203
Total	$	2,953,883		1,057,655

Fair value of warrant liability at November 30, 2016	$	168,070
Issuance of new warrant liability		-
Change in fair value of warrant liability		59,870
Reclassification of warrant liability to equity		(227,940	)
Fair value of warrant liability at August 31, 2017	$	-

								Weighted Average
				Weighted Average				Remaining Contractual
	Warrants			Exercise Price		Intrinsic Value		Life (years)
Outstanding at November 30, 2016		1,047,500		$	2.54	$	1,158,000		4.10
Issued		2,006,495			-		-		-
Exercised		(20,000	)		3.50		-		-
Outstanding at August 31, 2017		3,033,995		$	3.66	$	1,659,285		4.29
Exercisable at August 31, 2017		2,245,995		$	3.54	$	1,617,235		4.19

For the Three Months Ended

February 28, 2023

February 28, 2022

Consulting and legal expenses